

CITATION REPORT

List of articles citing

Triple-negative breast cancer: clinical features and patterns of recurrence

DOI: 10.1158/1078-0432.ccr-06-3045

Clinical Cancer Research, 2007, 13, 4429-34.

Source: <https://exaly.com/paper-pdf/42328848/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2217	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. 2011 , 121, 2750		11
2216	A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and poor outcome. 2010 , 4, 167		0
2215	Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. 1994 , 20, 987		1
2214	Distinct patterns of recurrence in triple-negative breast tumors. 2007 , 4, 618-618		
2213	Basic science: (AUGUST 2007). 2007 , 10,		
2212	Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. 2007 , 357, 1555; author reply 1556		78
2211	Triple negative tumours: a critical review. 2008 , 52, 108-18		640
2210	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. 2008 , 111, 27-44		257
2209	ERCC1 expression in triple negative breast carcinoma: the paradox revisited. 2008 , 111, 569-70		8
2208	Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases. 2008 , 112, 503-11		49
2207	Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. 2008 , 62, 667-72		74
2206	Analysis of the clinicopathologic features and prognosis in triple-negative breast cancer. 2008 , 5, 387-390		
2205	Update of evidence in chemotherapy for breast cancer. 2008 , 13, 3-7		15
2204	Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. 2008 , 72, 1056-63		33
2203	[Immunohistochemical characterisation of breast cancer: towards a new classification?]. 2008 , 84, 138-45		2
2202	The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. 2008 , 8, 307		92
2201	Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. 2008 , 8, 309		56

2200	Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. 2008 , 8 Suppl 4, S171-8		13
2199	Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). 2008 , 582, 4176-84		11
2198	Challenging patient populations in breast cancer: Taxane resistance and triple-negative receptor subtype. 2008 , 4, S40-S48		
2197	Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. 2008 , 8, 215-23		24
2196	[The use of breast cancer subtype classification to predict local and distant recurrence. A review]. 2008 , 12, 577-83		8
2195	What is triple-negative breast cancer?. 2008 , 44, 2799-805		230
2194	Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 5849-55	12.9	64
2193	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. 2008 , 26, 1275-81		1917
2192	Development of therapeutic approaches to 'triple negative' phenotype breast cancer. 2008 , 12, 1123-37		16
2191	Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. 2008 , 26, 1419-26		428
2190	Triple-negative breast cancer: risk factors to potential targets. <i>Clinical Cancer Research</i> , 2008 , 14, 8010-812.9		336
2189	Platinum-based chemotherapy in triple-negative breast cancer. 2008 , 19, 1847-52		167
2188	Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. 2008 , 26, 5393-400		74
2187	Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. 2008 , 26, 3324-30		578
2186	Breast cancer in young women: a new color or a different shade of pink?. 2008 , 26, 3303-5		6
2185	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. 2008 , 26, 4282-8		435
2184	Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I-III of operable patients. 2009 , 39, 97-104		18
2183	Triple-negative breast cancer and obesity in a rural Appalachian population. 2008 , 17, 3319-24		101

2182	Are triple-negative and basal-like breast cancer synonymous?. <i>Clinical Cancer Research</i> , 2008 , 14, 618; author reply 618-9	12.9	42
2181	Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. 2008 , 26, 2373-8		632
2180	Triple negative breast cancer: current understanding of biology and treatment options. 2008 , 20, 40-6		50
2179	Triple-negative breast cancer. 2008 , 20, 614-20		53
2178	Sternal resection for recurrent breast cancer: a cautionary tale. 2008 , 15, 193-5		6
2177	Factors Affecting the Ipsilateral Breast Tumor Recurrence after Breast Conserving Therapy in Patients with T1 and T2 Tumors. 2009 , 12, 324		3
2176	Management of advanced breast cancer with the epothilone B analog, ixabepilone. 2009 , 3, 163-71		7
2175	[Innovation in adjuvant radiotherapy for breast cancer: new biologic parameters, a perspective for treatment tailoring]. 2009 , 96, 111-21		1
2174	Prognostic Significance of Basal Markers in Triple-negative Breast Cancers. 2009 , 12, 4		11
2173	Basal Cytokeratin Expression in Relation to Immunohistochemical and Clinical Characterization in Breast Cancer Patients with Triple Negative Phenotype. 2009 , 95, 53-62		14
2172	Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. 2009 , 27, 4701-8		253
2171	Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. 2009 , 7, 4-13		457
2170	Triple-negative breast cancer: correlation between MR imaging and pathologic findings. 2009 , 250, 638-47		247
2169	Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. 2009 , 20, 628-35		158
2168	Distribution of Molecular Breast Cancer Subtypes in Middle Eastern-Saudi Arabian Women: A Pilot Study. 2009 , 33, 141-150		18
2167	Triple negative, basal-like and BRCA1-associated breast cancers – what’s the difference and should anyone care?. 2009 , 1, 59-61		
2166	Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetorelix with growth inhibition. 2009 , 35, 789-96		25
2165	Das tripelnegative/basale Mammakarzinom. 2009 , 69, 309-315		

2164	Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?. 2009 , 18, 1467-77	12
2163	What's positive about 'triple-negative' breast cancer?. 2009 , 5, 1015-25	19
2162	Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (. 2009 , 14, 1051-60	4
2161	Prognostic applications of gene expression signatures in breast cancer. 2009 , 77 Suppl 1, 2-8	18
2160	The role of VEGF in triple-negative breast cancer: where do we go from here?. 2009 , 20, 1615-7	14
2159	Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. 2009 , 20, 1639-46	216
2158	Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. 2009 , 20, 609-14	30
2157	Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?. 2009 , 18, 125-32	104
2156	High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. 2009 , 20, 1818-23	64
2155	Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. 2009 , 69, 3589-96	114
2154	p53 as a specific prognostic factor in triple-negative breast cancer. 2009 , 39, 217-24	62
2153	Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. 2009 , 19, 204-10	82
2152	Conditional independence relations among biological markers may improve clinical decision as in the case of triple negative breast cancers. 2009 , 10 Suppl 12, S13	4
2151	Triple negative breast carcinoma is a prognostic factor in Taiwanese women. 2009 , 9, 192	29
2150	Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. 2009 , 9, 342	27
2149	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. 2009 , 9, 86	213
2148	Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. 2009 , 9, 29-33	303
2147	Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. 2009 , 9, 96-100	51

2146	ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. 2009 , 1796, 162-75	79
2145	Therapeutic options for triple-negative breast cancers with defective homologous recombination. 2009 , 1796, 266-80	22
2144	Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. 2009 , 124, 1457-62	58
2143	Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. 2009 , 115, 4917-23	44
2142	Clinical characteristics and prognosis of triple-negative breast cancer. 2009 , 8, 471-475	2
2141	Pattern of metastatic spread in triple-negative breast cancer. 2009 , 115, 423-8	369
2140	Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. 2009 , 115, 325-33	79
2139	Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. 2009 , 117, 199-204	69
2138	Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. 2009 , 116, 273-9	27
2137	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. 2009 , 116, 317-28	150
2136	Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. 2009 , 118, 131-7	79
2135	Patho-biological aspects of basal-like breast cancer. 2009 , 113, 411-22	61
2134	Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. 2009 , 26, 372-8	27
2133	Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. 2009 , 16, 275-80	26
2132	Clinical significance of basal-like subtype in triple-negative breast cancer. 2009 , 16, 260-7	48
2131	Dual FGF-2 and integrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy. 2009 , 2, 33-47	21
2130	High cyclin B1 expression is associated with poor survival in breast cancer. 2009 , 100, 1055-60	87
2129	T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. 2009 , 15, 454-60	72

2128	Breast cancer subtypes and molecular biomarkers. 2009 , 15, 485-489	7
2127	Endogenous NIS expression in triple-negative breast cancers. 2009 , 16, 962-8	20
2126	The role of molecular analysis in breast cancer. 2009 , 41, 77-88	41
2125	Lymphangiogenic characteristics of triple negativity in node-negative breast cancer. 2009 , 17, 426-31	18
2124	Will MRI screening deliver the expected survival advantage in BRCA 1 carriers?. 2009 , 64, 1045-7	2
2123	Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. 2009 , 45, 2792-8	161
2122	Triple-negative breast cancer: novel therapies and new directions. 2009 , 63, 269-74	41
2121	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. 2009 , 9 Suppl 2, S73-81	424
2120	Triple-negative/basal-like breast cancer: review. 2009 , 41, 40-7	204
2119	The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. 2009 , 18, 883-93	168
2118	Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. 2009 , 11, R75	44
2117	Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. 2009 , 11, 208	10
2116	Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. 2009 , 11, R31	220
2115	Triple-negative breast cancer--current status and future directions. 2009 , 20, 1913-27	416
2114	Influence of obesity on breast cancer receptor status and prognosis. 2009 , 9, 1091-101	48
2113	PARP inhibitors: making progress toward individualized treatment in breast cancer. 2009 , 6, 342-343	
2112	Risk factors for triple-negative breast cancer in women under the age of 45 years. 2009 , 18, 1157-66	168
2111	Pathological definition of triple negative breast cancer. 2009 , 45 Suppl 1, 5-10	20

2110	Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. 2009 , 45 Suppl 1, 11-26	50
2109	Triple negative breast cancers: clinical and prognostic implications. 2009 , 45 Suppl 1, 27-40	173
2108	Pharmacotherapy of triple-negative breast cancer. 2009 , 10, 2081-93	26
2107	Triple-Negative Breast Carcinoma. 2009 , 2, 247-61	3
2106	Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. 2009 , 20, 172-174	
2105	Triple negative breast carcinomas: similarities and differences with basal like carcinomas. 2009 , 17, 483-94	17
2104	Triple Negative Breast Cancer: A Review. 2009 , 5, 149-156	
2103	Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. 2010 , 16, 23-32	106
2102	[Triple-negative breast carcinoma--review of current literature]. 2010 , 54, 325-35	2
2101	Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. 2010 , 23, 1213-20	24
2100	Clinicopathological features of breast cancer patients with nipple discharge. 2010 , 3, 863-8	1
2099	Developing an effective breast cancer vaccine. 2010 , 17, 183-90	30
2098	Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. 2010 , 17, 3252-8	13
2097	Triple-negative breast cancers: unique clinical presentations and outcomes. 2010 , 17 Suppl 3, 384-90	65
2096	Triple-negative breast cancer: correlation between imaging and pathological findings. 2010 , 20, 1111-7	128
2095	BRCA-Aktivität beim triple-negativen Mammakarzinom. 2010 , 43, 1002-1007	
2094	Clinicopathological features and treatment strategy for triple-negative breast cancer. 2010 , 15, 341-51	36
2093	Research progress in triple-negative breast cancer. 2010 , 9, 239-242	3

2092	Clinicopathologic features and related prognosis factors analysis of the basal and non-basal phenotype of triple negative breast cancer. 2010 , 9, 249-252	1
2091	BRCA1 and EGFR as prognostic biomarkers in triple negative metastatic breast cancer patients treated with cisplatin plus docetaxel. 2010 , 9, 700-707	2
2090	Triple-negative breast cancer. 2010 , 160, 174-81	23
2089	Triple Negative Breast Cancer. 2010 , 3, 185-189	
2088	Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer. 2010 , 6, 93-103	10
2087	Mechanisms of resistance to hormonal treatment in breast cancer. 2010 , 12, 246-52	12
2086	Current and emerging treatment options in triple-negative breast cancer. 2010 , 4, 5-13	3
2085	Clinicopathological characters of triple negative breast cancer. 2010 , 22, 17-20	4
2084	Patterns of relapse in breast cancer: changes over time. 2010 , 120, 753-9	25
2083	Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. 2010 , 123, 113-24	126
2082	A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (2010, 119, 653-61	56
2081	Adjuvant therapy of triple negative breast cancer. 2010 , 120, 285-91	36
2080	Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. 2010 , 120, 491-8	63
2079	Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. 2010 , 123, 177-87	40
2078	Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. 2010 , 37, 384-401	31
2077	Recurrent early-stage triple-negative breast cancer. 2010 , 37, 419-28	1
2076	Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. 2010 , 11, 277	64
2075	Advances in local-regional treatment for patients with early-stage breast cancer: a review of the field. 2010 , 10, 180-7	8

2074	Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. 2010 , 10, 294-300	89
2073	Novel treatment approaches for triple-negative breast cancer. 2010 , 10 Suppl 1, E16-22	19
2072	Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. 2010 , 10, 527	8
2071	Worsened oncologic outcomes for women of lower socio-economic status (SES) treated for locally advanced breast cancer (LABC) in Pakistan. 2010 , 19, 38-43	9
2070	Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. 2010 , 19, 246-8	57
2069	Management of triple negative breast cancer. 2010 , 19, 312-21	148
2068	Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. 2010 , 116, 538; author reply 538-9	1
2067	Reply to Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. 2010 , 116, 538-539	
2066	Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. 2010 , 116, 2549-59	68
2065	HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. 2010 , 127, 2707-17	26
2064	Optimal surgical treatment of breast cancer: implications for local control and survival. 2010 , 101, 677-86	8
2063	Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status. 2010 , 78, 799-803	18
2062	Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast. 2010 , 101, 1133-40	22
2061	Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. 2010 , 29, 2013-23	318
2060	Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. 2010 , 102, 369-75	80
2059	Cancer of the Breast. 2010 , 1215-1323	
2058	RB1CC1 together with RB1 and p53 predicts long-term survival in Japanese breast cancer patients. 2010 , 5, e15737	17
2057	Characteristics of Invasive Micropapillary Carcinoma of the Breast: In Comparison with Invasive Ductal Carcinoma. 2010 , 13, 174	2

2056	Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity. 2010 , 40, 112-8		35
2055	Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. 2010 , 70, 575-87		84
2054	Cancers du sein métastatiques « triples négatifs ». Critères cliniques et biologiques additionnels nécessaires pour prendre une décision thérapeutique. Stratégies thérapeutiques, place des anti-angiogéniques et nouvelles thérapeutiques ciblées. 2010 , 233-242		
2053	Breast conservation treatment with radiation: an ongoing success story. 2010 , 28, 709-11		15
2052	ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. 2010 , 51, 1565-72		77
2051	ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. 2010 , 9, 1503-14		15
2050	Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. 2010 , 34, 956-64		81
2049	A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 3607-17	12.9	90
2048	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 4702-10	12.9	120
2047	Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. <i>Clinical Cancer Research</i> , 2010 , 16, 6100-10	12.9	286
2046	Breast cancer subtypes and the risk of local and regional relapse. 2010 , 28, 1684-91		903
2045	Cancer du sein en situation métastatique. 2010 ,		
2044	Ovarian cancer: individualized and personalized care. 2010 , 5, 409-419		2
2043	FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. 2010 , 21, 1636-1642		24
2042	Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. 2010 , 10, 199-207		60
2041	Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls. 2010 , 10, 185-98		8
2040	FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. 2010 , 70, 3870-6		168
2039	Visible drug delivery by supramolecular nanocarriers directing to single-platformed diagnosis and therapy of pancreatic tumor model. 2010 , 70, 7031-41		119

2038	Vascular invasion in triple-negative carcinoma of the breast identified by endothelial lymphatic and blood vessel markers. 2010 , 18, 324-9	7
2037	Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17. 2010 , 4, 49-55	8
2036	Directed therapy of subtypes of triple-negative breast cancer. 2010 , 15 Suppl 5, 49-56	41
2035	D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. 2010 , 21, 1267-1272	62
2034	The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer. 2010 , 63, 240-3	15
2033	Beyond triple-negative breast cancer: the need to define new subtypes. 2010 , 10, 1197-213	17
2032	Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. 2010 , 70, 5465-74	58
2031	Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. 2010 , 12, e22	25
2030	Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel. 2010 , 21, 342-343	
2029	Influence of Isolated Tumor Cells in Sentinel Nodes on Outcome in Small, Node-Negative (pT1N0M0) Breast Cancer. 2010 , 21, 343-344	
2028	BRCA mutations in the management of breast cancer: the state of the art. 2010 , 7, 702-7	125
2027	Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. 2010 , 23, 123-33	175
2026	Triple-negative breast cancer. 2010 , 363, 1938-48	2458
2025	Triple-negative breast cancer. 2010 , 12 Suppl 2, S3	165
2024	Triple-negative breast cancer: present challenges and new perspectives. 2010 , 4, 209-29	212
2023	Tumor size and survival in breast cancer--a reappraisal. 2010 , 7, 348-53	82
2022	Treatment options for patients with triple-negative breast cancer. 2010 , 3, 42	45
2021	A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. 2010 , 12, R85	140

2020	Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. 2010 , 12, R99	117
2019	Triple-negative breast cancer: epidemiology and management options. 2010 , 70, 2247-58	81
2018	Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. 2010 , 10 Suppl 2, S20-9	11
2017	Does the PI3K pathway play a role in basal breast cancer?. 2010 , 10 Suppl 3, S66-71	21
2016	IMP3 expression in triple-negative breast carcinoma - Reply. 2010 , 41, 1356-1357	2
2015	Glioblastoma with signet-ring morphology. 2010 , 41, 1357; author reply 1357-8	
2014	Glioblastoma with signet-ring morphology. 2010 , 41, 1357	
2013	[Patient follow-up after treatment for breast cancer]. 2010 , 39, F85-8	0
2012	Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer. 2010 , 163, 52-7	20
2011	Interaction between menopausal status and obesity in affecting breast cancer risk. 2010 , 66, 33-8	121
2010	Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. 2010 , 36, 206-15	196
2009	Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?. 2010 , 36, 528-34	21
2008	Triple-negative breast cancer: a clinical update. 2010 , 7, 203-211	30
2007	Treatment of triple-negative breast cancer. 2010 , 7, 328-332	1
2006	Treatment of triple negative breast cancer (TNBC): current options and future perspectives. 2010 , 36 Suppl 3, S80-6	119
2005	The mammographic correlations with Basal-like phenotype of invasive breast cancer. 2010 , 17, 333-9	8
2004	Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. 2010 , 2, 55ra79	145
2003	Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?. 2010 , 19, 649-68	11

2002	Triple-negative breast cancer: disease entity or title of convenience?. 2010 , 7, 683-92	588
2001	Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. 2010 , 29, 39	11
2000	Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo. 2010 , 12, R49	32
1999	RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. 2010 , 12, R41	58
1998	The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. 2010 , 12, R18	91
1997	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. 2010 , 28, 375-9	417
1996	Triple-negative breast cancer: unique biology and its management. 2010 , 28, 878-83	11
1995	Whole blueberry powder modulates the growth and metastasis of MDA-MB-231 triple negative breast tumors in nude mice. 2011 , 141, 1805-12	42
1994	p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. 2011 , 41, 172-9	49
1993	Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. 2011 , 71, 7259-69	31
1992	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. 2011 , 24, 157-67	447
1991	Breast Cancer Subtypes and the Risk of Local and Regional Relapse: Voduc KD, Cheang MCU, Tyldesley S, et al (British Columbia Cancer Agency, Vancouver, Canada; Univ of British Columbia, Vancouver; Univ of North Carolina at Chapel Hill) J Clin Oncol 28:1684-1691, 2010. 2011 , 22, 302-304	1
1990	New treatment strategies in the management of breast cancer. 2011 , 9, 22-29	2
1989	Case histories: breast cancer. 2011 , 9, 36-42	
1988	Recent developments in treatment stratification for metastatic breast cancer. 2011 , 71, 2099-113	10
1987	Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez). 2011 , 4, 500	14
1986	Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. 2011 , 11, 147-57	8
1985	Cancer Systems Biology, Bioinformatics and Medicine. 2011 ,	3

1984	Current treatment options in triple negative breast cancer. 2010 , 32, 99-122	38
1983	Triple negative breast cancer: adjuvant chemotherapy effect on survival. 2011 , 56, 285-90	6
1982	Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. 2011 , 47, 1578-84	85
1981	Differential phosphopeptide expression in a benign breast tissue, and triple-negative primary and metastatic breast cancer tissues from the same African-American woman by LC-LTQ/FT-ICR mass spectrometry. 2011 , 412, 127-31	9
1980	A Perturbation Method for Inference on Regularized Regression Estimates. 2011 , 106, 1371-1382	53
1979	Human epidermal growth factor receptor 2, Na ⁺ /H ⁺ exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. 2011 , 42, 1589-95	14
1978	Proteomics and biomarkers in clinical trials for drug development. 2011 , 74, 2632-41	58
1977	Capturing changes in gene expression dynamics by gene set differential coordination analysis. 2011 , 98, 469-77	11
1976	Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. 2011 , 13, R35	86
1975	Implications of genomic instability in the diagnosis and treatment of breast cancer. 2011 , 11, 445-53	26
1974	Gene signatures of breast cancer progression and metastasis. 2011 , 13, 201	33
1973	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. 2011 , 13, R22	158
1972	Challenges to developing proteomic-based breast cancer diagnostics. 2011 , 15, 251-9	18
1971	Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. 2011 , 3, 64ra2	204
1970	Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast irradiation. 2011 , 81, e159-64	18
1969	Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. 2011 , 18, 180-90	19
1968	A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. 2011 , 18, 191-6	15
1967	Triple-negative breast cancers: an updated review on treatment options. 2011 , 18, e173-9	54

1966	Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. 2011 , 3, 9-19	11
1965	Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. 2011 , 2, 257-264	16
1964	Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. 2011 , 14, 46-51	26
1963	Breast Cancer: Classification Based on Molecular Etiology Influencing Prognosis and Prediction. 2011 ,	3
1962	B-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer. 2011 , 14, 14-9	26
1961	Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. 2011 , 66, 607-12	12
1960	Clinical trials in triple negative breast cancer. 2010 , 32, 123-36	24
1959	The implications of breast cancer molecular phenotype for radiation oncology. 2011 , 1, 12	8
1958	Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. 2011 , 6, e28222	21
1957	Triple-Negative Breast Cancer: Clinical and Histological Correlations. 2011 , 6, 273-278	31
1956	Molecular heterogeneity of triple-negative breast cancer and its clinical implications. 2011 , 23, 566-77	62
1955	PARP inhibition: opening up new horizons?. 2011 , 1, 759-762	
1954	Breast Cancer Subtypes and the Risk of Local and Regional Relapse. 2011 , 2011, 57-60	1
1953	Etiology and risk factors. 2011 , 6-15	
1952	Triple-negative breast cancer and new treatment developments. 2011 , 1, 1107-1118	
1951	Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. 2011 , 25, 1481-7	32
1950	Elevated expression of squamous cell carcinoma antigen (SCCA) is associated with human breast carcinoma. 2011 , 6, e19096	39
1949	Cisplatin and TRAIL enhance breast cancer stem cell death. 2011 , 39, 891-8	25

1948	Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. 2011 , 108, 323-30	82
1947	Triple negative and basal-like breast cancer in East Africa. 2011 , 17, 438-40	9
1946	Prognostic impact of triple negative phenotype in conservatively treated breast cancer. 2011 , 17, 377-82	6
1945	Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. 2011 , 119, 103-10	10
1944	Molecular predictors of local tumor control in early-stage breast cancer. 2011 , 21, 35-42	11
1943	Adjuvant therapies for special types of breast cancer. 2011 , 20 Suppl 3, S153-7	22
1942	Triple-negative breast cancer: what the radiologist needs to know. 2011 , 46, 26-39	25
1941	"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. 2011 , 38, 254-62	18
1940	Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. 2011 , 90, 116-22	29
1939	Improving gene expression data interpretation by finding latent factors that co-regulate gene modules with clinical factors. 2011 , 12, 563	3
1938	Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. 2011 , 11, 27-32	38
1937	Metastatic triple-negative breast cancer. 2011 , 23, 587-600	81
1936	Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome. 2011 , 11, 153-60	15
1935	Recommendation to revise the AJCC/UICC breast cancer staging system for inclusion of proven prognostic factors: ER/PR receptor status and HER2 neu. 2011 , 11, 346-7	5
1934	Breast cancer subtype-specific interactions with the microenvironment dictate mechanisms of invasion. 2011 , 71, 6857-66	50
1933	Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study. 2011 , 18, 3839-47	29
1932	Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. 2011 , 18, 2851-7	73
1931	The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. 2011 , 18, 2858-65	36

1930	Triple-negative breast cancer is not a contraindication for breast conservation. 2011 , 18, 3164-73	78
1929	Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer. 2011 , 16, 41-50	17
1928	Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. 2011 , 127, 471-8	118
1927	Triple negative breast cancer: unmet medical needs. 2011 , 125, 627-36	226
1926	Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. 2011 , 128, 259-66	25
1925	Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. 2011 , 127, 287-96	66
1924	The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. 2011 , 126, 471-8	101
1923	IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. 2011 , 130, 465-75	41
1922	The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. 2011 , 128, 581-3	23
1921	Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. 2011 , 128, 899-906	70
1920	Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. 2011 , 128, 155-63	107
1919	Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. 2011 , 129, 867-75	40
1918	Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. 2011 , 130, 145-53	79
1917	Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. 2011 , 22, 775-83	57
1916	Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes. 2011 , 105, 547-53	12
1915	Characteristics of triple-negative breast cancer. 2011 , 137, 183-92	172
1914	Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. 2011 , 137, 1505-10	29
1913	Clinicopathological features of triple-negative breast cancer in Taiwanese women. 2011 , 16, 500-5	12

1912	Breast cancer metastatic to the rectum: a case report. 2011 , 15 Suppl 1, S91-3	9
1911	HER2 gene status and the relationship with p21 protein expression in gastric cancer. 2011 , 10, 162-165	
1910	Triple negative breast cancer: 5 years follow-up. 2011 , 10, 317-320	1
1909	Prognostic factors affecting postmastectomy locoregional recurrence in patients with early breast cancer: are intrinsic subtypes effective?. 2011 , 35, 2196-202	13
1908	Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). 2011 , 68, 753-61	21
1907	Aspirin intake may prevent metastasis in patients with triple-negative breast cancer. 2011 , 28, 1308-10	4
1906	Bcl-2 expression and triple negative profile in breast carcinoma. 2011 , 28 Suppl 1, S55-61	24
1905	Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. 2011 , 28 Suppl 1, S75-9	7
1904	CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. 2011 , 28 Suppl 1, S129-34	25
1903	PARP Inhibitors. 2011 , 3, 44-54	6
1902	How do I treat "triple-negative" disease. 2011 , 12, 369-88	8
1901	Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. 2011 , 11, 250	53
1900	Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?. 2011 , 11, 299	37
1899	Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. 2011 , 4, 14	28
1898	Systemic treatment of early breast cancer--a biological perspective. 2011 , 103, 619-26	7
1897	Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. 2011 , 117, 3093-100	60
1896	Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. 2011 , 117, 3658-69	134
1895	Impact of body mass index on clinical outcomes in triple-negative breast cancer. 2011 , 117, 4132-40	66

1894	Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. 2011 , 80, 1095-101	42
1893	The changing role of pathology in breast cancer diagnosis and treatment. 2011 , 78, 99-114	77
1892	Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?. 2011 , 8, 669-679	5
1891	Exploring molecular pathways of triple-negative breast cancer. 2011 , 2, 870-9	57
1890	RUNX1 and its understudied role in breast cancer. 2011 , 10, 3461-5	48
1889	Triple negative breast cancer - prognostic factors and survival. 2011 , 45, 46-52	124
1888	Overexpression of c-KIT (CD117) in triple-negative breast cancer. 2011 , 31, 113-117	4
1887	Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. 2011 , 10, 550-7	32
1886	Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7194-203 ^{12.9}	18
1885	Monitoring the response to primary medical therapy for breast cancer using three- dimensional time-resolved optical mammography. 2011 , 10, 533-47	11
1884	Triple-negative breast cancer in Lebanon: a case series. 2011 , 16, 1552-6	7
1883	Handbook of Metastatic Breast Cancer. 2011 ,	
1882	Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?. 2011 , 103, 451-3	36
1881	Triple-negative breast cancer: adjuvant therapeutic options. 2011 , 2011, 696208	43
1880	Management options in triple-negative breast cancer. 2011 , 5, 175-99	29
1879	Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. 2011 , 29, 2628-34	102
1878	Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers?. 2011 , 29, 2841-3	11
1877	Directed therapy of subtypes of triple-negative breast cancer. 2011 , 16 Suppl 1, 71-8	126

1876	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. 2011 , 25, 199-211	118
1875	Molecular and functional imaging of invasion and metastasis: windows into the metastatic cascade. 2010 , 7, 173-88	6
1874	YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. 2011 , 39, 569-75	37
1873	Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. 2011 , 29, 2852-8	249
1872	Triple-negative breast cancer: an unmet medical need. 2011 , 16 Suppl 1, 1-11	542
1871	Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. <i>Clinical Cancer Research</i> , 2011 , 17, 5432-42	12.9 31
1870	Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron. 2011 , 286, 41413-41424	58
1869	Clinical relevance of TNM staging system according to breast cancer subtypes. 2011 , 22, 1554-1560	69
1868	B-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells. 2011 , 9, 1632-43	47
1867	Basal phenotype breast cancer: implications for treatment and prognosis. 2011 , 7, 181-202	19
1866	Old and new concepts in histopathological characterization of familial breast cancer. 2011 , 22 Suppl 1, i24-30	11
1865	Management of primary and metastatic triple negative breast cancer: perceptions of oncologists from India. 2011 , 48, 158-64	2
1864	Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients. 2011 , 29, 180-6	3
1863	Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. 2011 , 22, 1571-1581	31
1862	Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer. 2011 , 80, 341-9	11
1861	Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. 2011 , 48, 391-6	63
1860	Outcomes of surveillance for contralateral breast cancer in patients less than age 60 at the time of initial diagnosis. 2012 , 19, e160-4	9
1859	TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. 2012 , 11, 147-56	161

1858	Locoregional treatments for triple-negative breast cancer. 2012 , 23 Suppl 6, vi30-4	13
1857	Tumour size predicts long-term survival among women with lymph node-positive breast cancer. 2012 , 19, 249-53	39
1856	Targeting triple-negative breast cancer: optimising therapeutic outcomes. 2012 , 23, 2223-2234	120
1855	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. 2012 , 109, 2766-71	156
1854	Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. 2012 , 23 Suppl 6, vi19-22	90
1853	Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer. 2012 , 35, 242-6	6
1852	The significance of immunohistochemical expression of maspin in basal-like breast cancer. 2012 , 32, 204-210	1
1851	Triple-negative breast cancer: are we making headway at least?. 2012 , 4, 195-210	60
1850	Triple receptor-negative breast cancer: imaging and clinical characteristics. 2012 , 199, 458-64	68
1849	Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. 2012 , 96, 123-32	109
1848	Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. 2012 , 13, 1123-40	36
1847	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. 2012 , 209, 679-96	252
1846	Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. 2012 , 20, 139-45	59
1845	Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells. 2012 , 287, 42502-15	38
1844	Unresectable Metastatic Colorectal Cancer Treatment and Survival âPauls Stradins Clinical University Hospital Experience. 2012 , 12, 15-19	
1843	Expected net present value of sample information: from burden to investment. 2012 , 32, E11-21	26
1842	The prognostic value of triple negative in stage II/III breast cancer. 2012 , 18, 68-75	10
1841	A 10-year follow-up of triple-negative breast cancer patients in Taiwan. 2012 , 42, 161-7	10

1840	Molecular basis of triple negative breast cancer and implications for therapy. 2012 , 2012, 217185	77
1839	Metabolic syndrome and triple-negative breast cancer: a new paradigm. 2012 , 2012, 809291	63
1838	Transcriptomic landscape of breast cancers through mRNA sequencing. 2012 , 2, 264	67
1837	Identification of new candidate therapeutic target genes in triple-negative breast cancer. 2012 , 3, 63-70	22
1836	Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH). 2012 , 9, 87-94	4
1835	Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China. 2012 , 7, 13-17	15
1834	Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. 2012 , 5, 687-92	7
1833	Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer. 2012 , 3, 163-171	40
1832	A gene signature for predicting outcome in patients with basal-like breast cancer. 2012 , 2, 227	48
1831	Clinicopathologic features and prognosis of triple-negative breast cancer in patients 40 years of age and younger in Saudi Arabia. 2012 , 5, 101-6	11
1830	Basal breast cancer: a complex and deadly molecular subtype. 2012 , 12, 96-110	139
1829	Vaccinia virus GLV-1h153 is effective in treating and preventing metastatic triple-negative breast cancer. 2012 , 256, 437-45	19
1828	Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. 2012 , 23, 426-36	20
1827	Sonographic features of triple-negative and non-triple-negative breast cancer. 2012 , 31, 1531-41	52
1826	Challenges and opportunities in the design and implementation of breast cancer clinical trials in developing countries. 2012 , 2, 579-587	4
1825	Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. 2012 , 38, 698-707	342
1824	The impact of curcumin on breast cancer. 2012 , 4, 996-1007	61
1823	Molecular pathology of breast cancer: what a pathologist needs to know. 2012 , 138, 770-80	66

1822 Cancers du sein triples ngatifs: Une revue de la littfature. **2012**, 571-588

1821	Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. 2012 , 14, R22	59
1820	Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. 2012 , 14, R62	99
1819	Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. 2012 , 14, R79	175
1818	Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. 2012 , 138, 511-6	60
1817	Controverse: utilitdes agonistes de la GnRH en protection ovarienne en cours de chimiothfapie pour cancer du sein. 2012 , 14, 386-394	
1816	Tumour characteristics among women with very low-risk breast cancer. 2012 , 134, 1241-6	11
1815	A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. 2012 , 136, 487-93	106
1814	Role of epidermal growth factor receptor in breast cancer. 2012 , 136, 331-45	371
1813	Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. 2012 , 136, 795-804	115
1812	Association between African American race and outcomes in patients with nonmetastatic triple-negative breast cancer: a retrospective analysis by using results from the Georgia Cancer Specialist Database. 2012 , 12, 270-5	18
1811	Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. 2012 , 12, 364-72	48
1810	Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy. 2012 , 84, 1123-32	35
1809	Invasive lobular carcinoma predicts micrometastasis in breast cancer. 2012 , 177, 93-6	10
1808	Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer. 2012 , 33, 1681-94	20
1807	Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: A retrospective clinical study: Sanpaolo P, Barbieri V, Genovesi D (CROB, Rionero in Vulture (PZ), Italy; â. D'Annunzioâ Univ, Via dei Vestini, Chieti, Italy) Eur J Surg Oncol 37:876-882, 2011. 2012 , 23, 45-47	
1806	Características de imagen del carcinoma triple negativo. 2012 , 25, 22-31	2
1805	Immunohistochemical profile and clinical-pathological variables in breast cancer. 2012 , 58, 178-187	

1804	Perfil imuno-histoquímico e variáveis clinicopatológicas no câncer de mama. 2012 , 58, 178-187	7
1803	Postmastectomy chest wall radiotherapy with single low-energy electron beam: An assessment of outcome and prognostic factors. 2012 , 2, 106-13	2
1802	Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. 2012 , 28, 419-28	24
1801	ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer. 2012 , 19, 3159-64	11
1800	The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression. 2012 , 287, 24631-40	69
1799	Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. 2012 , 19, 3506-14	49
1798	Differential influence of dietary soy intake on the risk of breast cancer recurrence related to HER2 status. 2012 , 64, 198-205	26
1797	Progranulin expression in breast cancer with different intrinsic subtypes. 2012 , 208, 210-6	14
1796	Molecular subtypes of breast carcinoma in Egyptian women: clinicopathological features. 2012 , 208, 382-6	19
1795	Early stage triple negative and HER2 overexpression breast cancers have similar survivals in Chinese patients. 2012 , 18, 286-8	
1794	Limited overall survival in patients with brain metastases from triple negative breast cancer. 2012 , 18, 345-50	24
1793	Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. 2012 , 23, 2572-2577	75
1792	Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. 2012 , 181, 257-67	65
1791	Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers. 2012 , 424, 34-9	29
1790	Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. 2012 , 149, 780-94	525
1789	Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (. 2012 , 48, 2962-8	20
1788	The prognostic value of tumour-stroma ratio in triple-negative breast cancer. 2012 , 38, 307-13	86
1787	Dissecting the heterogeneity of triple-negative breast cancer. 2012 , 30, 1879-87	304

1786	A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. 2012 , 12, 120	103
1785	Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. 2012 , 12, 35	19
1784	Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. 2012 , 103, 1665-71	78
1783	B-crystallin is a useful marker for triple negative and basal breast cancers. 2012 , 61, 378-86	25
1782	Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. 2012 , 8, 703-11	20
1781	First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. 2012 , 82, 218-27	38
1780	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. 2012 , 23 Suppl 6, vi46-51	183
1779	Molecular Classification of Breast Cancer. 2012 , 5, 701-17	5
1778	Notch signaling and breast cancer. 2012 , 727, 241-57	60
1777	Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF- κ B activity via the Notch-1 pathway. 2012 , 30, 337-43	117
1776	[A case of cutaneous mammary re-irradiation]. 2012 , 16, 638-40	
1775	Retrospective study of patients with metastatic triple-negative breast cancer: survival, health care utilization, and cost. 2012 , 9, 8-14	3
1774	Burden of Early-Stage Triple-Negative Breast Cancer in a US Managed Care Plan. 2012 , 3, e57-e65	2
1773	Patients younger than 40years old and older than 70years old affected by ER(+)PR(+)HER2(+) breast cancer have low survival rates: Results of a mono-institutional retrospective analysis. 2012 , 3, 312-319	
1772	Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. 2012 , 65, 45-61	50
1771	Leptin and breast cancer: an overview. 2012 , 29, 1510-4	38
1770	Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. 2012 , 12, 18	23
1769	Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. 2012 , 10 Suppl 1, S4	23

1768	Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. 2012 , 7, e31070	39
1767	Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. 2012 , 7, e37624	50
1766	Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up. 2012 , 99, E64-74	3
1765	Update on triple-negative breast cancer: prognosis and management strategies. 2012 , 4, 511-20	76
1764	Outcome Evaluation in Pre-Trastuzumab Era between Different Breast Cancer Phenotypes: A Population-Based Study on Italian Women. 2012 , 98, 743-750	9
1763	Triple Negative Breast Cancer - An Overview. 2013 , 2013,	61
1762	Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. 2012 , 15, 197-202	18
1761	The Risk Factors Influencing between the Early and Late Recurrence in Systemic Recurrent Breast Cancer. 2012 , 15, 218-23	21
1760	Ductal carcinoma in situ: challenges, opportunities, and uncharted waters. 2012 , 40-4	5
1759	Association of D4-GDI expression with breast cancer progression. 2011 , 10, 163-73	4
1758	Size surprise? Tumour size, nodal status, and outcome after breast cancer. 2012 , 19, 241-3	13
1757	Realizing the promise of breast cancer vaccines. 2012 , 35	
1756	Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. 2012 , 30, 1338-48	52
1755	Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. 2012 , 149, 1284-97	353
1754	A fatty acid-binding protein 7/RXR α pathway enhances survival and proliferation in triple-negative breast cancer. 2012 , 228, 310-21	39
1753	Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study. 2012 , 1, 89-95	5
1752	The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. 2012 , 118, 2780-6	20
1751	Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy. 2012 , 118, 3893-8	20

1750	Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. 2012 , 118, 4944-52	49
1749	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. 2012 , 118, 5463-72	343
1748	Cytologic features of triple-negative breast carcinoma. 2012 , 120, 401-9	11
1747	Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor- β 6 (ER β 6). 2012 , 287, 7169-81	79
1746	Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. 2012 , 132, 793-805	205
1745	Triple negative breast cancer - our experience and review. 2012 , 3, 12-6	27
1744	Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. 2012 , 134, 353-62	73
1743	Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. 2012 , 134, 277-82	54
1742	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. 2012 , 134, 683-92	55
1741	Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. 2012 , 134, 561-7	54
1740	Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. 2012 , 134, 793-800	13
1739	EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. 2012 , 29, 401-5	59
1738	Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. 2012 , 29, 406-10	116
1737	Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. 2012 , 29, 547-53	10
1736	Outcome of non-metastatic male breast cancer: 118 patients. 2012 , 29, 554-60	40
1735	Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. 2012 , 22, 1724-34	153
1734	IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. 2012 , 133, 563-73	58
1733	Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer. 2012 , 133, 909-16	25

1732	Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. 2012 , 133, 831-41	277
1731	Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. 2012 , 133, 1067-75	82
1730	The paradox of triple negative breast cancer: novel approaches to treatment. 2012 , 18, 41-51	52
1729	Predicting the likelihood of nonsentinel lymph node metastases in triple negative breast cancer patients with a positive sentinel lymph node: Turkish Federation of Breast Disease Associations protocol MF09-01. 2012 , 12, 63-7	3
1728	Neoadjuvant therapy in early-stage breast cancer. 2012 , 82, 187-99	14
1727	Adjuvant early breast cancer systemic therapies according to daily used technologies. 2012 , 82, 361-9	8
1726	Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. 2012 , 21, 20-6	24
1725	Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. 2012 , 21, 272-5	13
1724	Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. 2012 , 21, 276-83	16
1723	Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?. 2012 , 21, 604-7	13
1722	Is conservative surgery a good option for patients with "triple negative" breast cancer?. 2012 , 21, 401-5	2
1721	Triple-negative breast cancer: making the most of a misnomer. 2012 , 8, 145-55	9
1720	Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. 2012 , 75, 3031-40	77
1719	Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. 2012 , 103, 382-9	123
1718	Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. 2012 , 51, 375-83	26
1717	Treatment of Metastatic Triple-Negative Breast Cancer. 2012 , 4, 10-21	
1716	Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. 2012 , 131, 1061-6	176
1715	Metabolic phenotypes in triple-negative breast cancer. 2013 , 34, 1699-712	42

1714	The role of the androgen receptor in triple-negative breast cancer. 2013 , 9, 351-60	32
1713	Relapsed triple-negative breast cancer: challenges and treatment strategies. 2013 , 73, 1257-65	34
1712	Detection of cancer before distant metastasis. 2013 , 13, 283	47
1711	Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. 2013 , 13, 225	37
1710	Caractéristiques des carcinomes mammaires triple-négatifs dans l'ouest-algérien. 2013 , 5, 155-161	2
1709	Vimentin as a poor prognostic factor for triple-negative breast cancer. 2013 , 139, 739-46	87
1708	The management of early-stage and metastatic triple-negative breast cancer: a review. 2013 , 27, 737-49, viii	64
1707	LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. 2013 , 141, 89-99	58
1706	Quantitative proteomic studies on TNBC in premenopausal patients. 2013 , 29, 500-505	1
1705	Breast Cancer Heterogeneity in Primary and Metastatic Disease. 2013 , 65-95	1
1704	The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. 2013 , 138, 783-94	58
1703	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. 2013 , 14, 933-42	318
1702	Triple-negative breast cancer and the need for new therapeutic targets. 2013 , 183, 1064-1074	110
1701	Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. 2013 , 22, 823-40	22
1700	Molecular pathways: PI3K pathway targets in triple-negative breast cancers. <i>Clinical Cancer Research</i> , 2013 , 19, 3738-44	12.9 49
1699	Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society. 2013 , 24, 2298-304	13
1698	Biology of the estrogen receptor, GPR30, in triple negative breast cancer. 2013 , 206, 698-703	40
1697	Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy. 2013 , 13, 40-6	8

1696	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 5505-12	12.9	443
1695	BRCAness: a deeper insight into basal-like breast tumors. 2013 , 24 Suppl 8, viii13-viii21		47
1694	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. 2013 , 15, R88		139
1693	Family history and risk of ductal carcinoma in situ and triple negative breast cancer in a Han Chinese population: a case-control study. 2013 , 11, 248		9
1692	Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. 2013 , 30, 631-42		24
1691	Outcomes of delays in time to treatment in triple negative breast cancer. 2013 , 20, 1880-5		18
1690	Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. 2013 , 11, 280		106
1689	Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis. 2013 , 63, 509-19		28
1688	Mammographic and ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes. 2013 , 54, 889-94		22
1687	Cancer dormancy: time to explore its clinical relevance. 2013 , 15, 321		9
1686	Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers. 2013 , 148, 298-306		40
1685	Prognostic impact of FOXP3 expression in triple-negative breast cancer. 2013 , 52, 73-81		61
1684	High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGF β pathways as fundamental Notch regulators in breast cancer. 2013 , 110, 1714-9		89
1683	Lack of expression of the proteins GMPR2 and PPAR α are associated with the basal phenotype and patient outcome in breast cancer. 2013 , 137, 127-37		15
1682	Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. 2013 , 137, 307-14		225
1681	Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. 2013 , 137, 119-25		44
1680	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. 2013 , 137, 483-92		82
1679	Assessing the role of ultrasound in predicting the biological behavior of breast cancer. 2013 , 200, 284-90		54

1678	Distribuci3n fenot3pica del carcinoma de mama en Venezuela. 2013 , 26, 129-133	
1677	Differences in breast cancer hormone receptor status in ethnic groups: a London population. 2013 , 49, 696-702	31
1676	Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. 2013 , 22, 986-92	31
1675	The evolution in management of patients with subcentimeter, node-negative, triple-negative breast cancer. 2013 , 206, 888-92; discussion 892-3	2
1674	Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. 2013 , 34, 10160-71	95
1673	Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel. 2013 , 22, 1142-7	5
1672	Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. 2013 , 13, 416-20	45
1671	Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. 2013 , 288, 17954-67	102
1670	Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. 2013 , 439, 275-9	40
1669	Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. 2013 , 30, 388	92
1668	Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer. 2013 , 30, 468	8
1667	Therapeutic targets in triple negative breast cancer. 2013 , 66, 530-42	104
1666	High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. 2013 , 108, 1100-5	57
1665	Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. 2013 , 24, 1498-505	50
1664	Resistance to BRAF-targeted therapy in melanoma. 2013 , 49, 1297-304	273
1663	Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. 2013 , 80, 41-52	62
1662	Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. 2013 , 14, 246-53	25
1661	Metastasis awakening: the challenges of targeting minimal residual cancer. 2013 , 19, 274-5	45

1660	Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer. 2013 , 30, 477	62
1659	Emerging therapies for triple-negative breast cancer. 2013 , 2, 47-55	0
1658	Diagnostic and prognostic value of plasma and tissue ubiquitin-like, containing PHD and RING finger domains 1 in breast cancer patients. 2013 , 104, 194-9	26
1657	Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. 2013 , 23, 2420-31	73
1656	Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. 2013 , 54, 334-45	43
1655	Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. 2013 , 139, 905-14	4
1654	Transducer of Cdc42-dependent actin assembly promotes breast cancer invasion and metastasis. 2013 , 32, 3080-90	31
1653	Hereditary breast and ovarian cancer susceptibility genes (review). 2013 , 30, 1019-29	97
1652	The functional role of Notch signaling in triple-negative breast cancer. 2013 , 93, 277-306	28
1651	Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. 2013 , 26, 955-66	63
1650	Triple negative breast cancer: clinical characteristics in the different histological subtypes. 2013 , 22, 761-6	38
1649	Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. 2013 , 139, 155-61	48
1648	Trends in polymeric delivery of nucleic acids to tumors. 2013 , 170, 209-18	28
1647	Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. 2013 , 33, 262-265	5
1646	Aspects cliniques et pronostiques des cancers du sein triple négatifs à l'Unité de Sthologie du CHU Le-Dantec de Dakar. 2013 , 5, 42-47	2
1645	DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. 2013 , 18, 1063-73	64
1644	Racial differences in outcomes of triple-negative breast cancer. 2013 , 138, 281-9	29
1643	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. 2013 , 138, 273-9	25

1642	Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. 2013 , 20, 3469-76	95
1641	Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers. 2013 , 109, 2347-55	10
1640	Targeted approaches to triple-negative breast cancer: current practice and future directions. 2013 , 20, 605-12	15
1639	Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. 2013 , 269, 354-61	19
1638	Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. 2013 , 24, 1491-8	57
1637	Are two-centimeter breast cancers large or small?. 2013 , 20, 205-11	4
1636	Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. 2013 , 43, 1985-91	30
1635	Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. 2013 , 18, 141-7	29
1634	In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. 2013 , 24, 104-11	8
1633	Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients. A prospective, open, and unicentric Phase II clinical trial. 2013 , 36, 545-51	7
1632	Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. 2013 , 3, 922-35	32
1631	[Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]. 2013 , 100, 453-64	14
1630	Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. 2013 , 51, 1511-9	37
1629	Radiation treatments after breast-conserving therapy for elderly patients. 2013 , 31, 2367-8	16
1628	Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response. 2013 , 59, 387-94	15
1627	Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. 2013 , 20, 797-808	75
1626	An Integrative Genomics Approach for Associating GWAS Information with Triple-Negative Breast Cancer. 2013 , 12, 1-20	14
1625	Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer. 2013 , 2013, 250435	47

1624	Epidemiological and clinical profile of triple negative breast cancer at a cancer hospital in North India. 2013 , 34, 89-95	15
1623	Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. 2013 , 12, 2043-54	37
1622	Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico. 2013 , 2, 343-50	15
1621	MR imaging features of triple-negative breast cancers. 2013 , 19, 643-9	47
1620	Landmark risk prediction of residual life for breast cancer survival. 2013 , 32, 3459-71	9
1619	Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors. 2013 , 119, 2366-74	23
1618	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. 2013 , 5, 169-81	121
1617	Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. 2013 , 2, 571-82	55
1616	The challenges of individualized care for older patients with localized breast cancer. 2013 , 13, 963-73	
1615	Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. 2013 , 31, 2586-92	255
1614	Triple-negative breast cancers: associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers. 2013 , 18, 802-11	47
1613	Integrating molecular biology into clinical practice. 2013 , 31, 2222	1
1612	Activity assay of epidermal growth factor receptor tyrosine kinase inhibitors in triple-negative breast cancer cells using peptide-conjugated magnetic beads. 2013 , 11, 44-51	
1611	Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. 2013 , 4, e891	85
1610	ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome. 2013 , 109, 109-13	29
1609	Triple-negative breast cancer: molecular characterization and targeted therapies. 2013 , 2, 417-430	1
1608	Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer. 2013 , 139, 746-53	23
1607	Estrogen receptor β putting a positive into triple negative breast cancer?. 2013 , 16, 117-23	6

1606	Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells. 2013 , 36, 1921-7	16
1605	Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. 2013 , 15, R98	69
1604	HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. 2013 , 6, 13-18	16
1603	NCCN News. 2013 , 11, xxxiv-xxxvi	
1602	Expression of cell metabolism-related genes in different molecular subtypes of triple-negative breast cancer. 2013 , 99, 555-564	5
1601	New developments in breast cancer prognosis: molecular predictors of treatment response and survival. 2013 , 28, 131-40	3
1600	Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. 2013 , 15, 208	81
1599	An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. 2013 , 15, R103	25
1598	Study of the Carrier State for Five BRCA1/BRCA2 Deleterious Mutations in Bulgarian Women with Breast Cancer. 2013 , 6, 100-105	1
1597	Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. 2013 , 2, 325-34	6
1596	New criteria to predict tumor recurrence in invasive ductal carcinoma of the breast. 2013 , 98, 283-8	1
1595	Knockdown of TRB3 induces apoptosis in human lung adenocarcinoma cells through regulation of Notch 1 expression. 2013 , 8, 47-52	33
1594	Identification of plant extracts sensitizing breast cancer cells to TRAIL. 2013 , 29, 1991-8	14
1593	Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. 2013 , 24, 150-7	15
1592	Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. 2013 , 30, 413-8	23
1591	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer. 2013 , 5, 27-35	2
1590	The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. 2013 , 5, 353-70	24
1589	Distribution of CXCR4 and Eatenin expression pattern in breast cancer subtypes and their relationship to axillary nodal involvement. 2013 , 64, 253-9	7

1588	Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. 2013 , 6, 883-8	41
1587	Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer. 2013 , 99, 545-554	4
1586	Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells. 2013 , 18, 133-44	18
1585	Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. 2013 , 8, e56919	48
1584	miR-221 promotes tumorigenesis in human triple negative breast cancer cells. 2013 , 8, e62170	75
1583	Triple negative breast cancers have a reduced expression of DNA repair genes. 2013 , 8, e66243	27
1582	Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. 2013 , 8, e76340	57
1581	Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation. 2013 , 16, 308-14	22
1580	Distant metastasis in triple-negative breast cancer. 2013 , 60, 290-4	69
1579	Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?. 2013 , 2013, 964863	16
1578	PathAct: a novel method for pathway analysis using gene expression profiles. 2013 , 9, 394-400	5
1577	Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. 2014 , 9, e81126	33
1576	Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer. 2014 , 9, e98370	57
1575	A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. 2014 , 9, e100664	49
1574	The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFR β closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. 2014 , 9, e102176	37
1573	Synthesis, characterization and in vitro study of biocompatible cinnamaldehyde functionalized magnetite nanoparticles (CPGF Nps) for hyperthermia and drug delivery applications in breast cancer. 2014 , 9, e107315	44
1572	A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer. 2014 , 9, e112765	27
1571	Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. 2014 , 9, e114900	48

1570	Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy. 2014 , 6, 151-8	7
1569	Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer. 2014 , 18, 34-8	4
1568	Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. 2014 , 17, 439-46	33
1567	Autoantibodies in breast cancer. 2014 , 64, 221-40	5
1566	Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis. 2014 , 7, 1733-42	28
1565	Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry. 2014 , 17, 129-35	10
1564	Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. 2014 , 5, 2736-49	219
1563	Prevalence of the Triple-Negative Phenotype in Mexican Patients with Breast Cancer Treated in Private Practice. 2014 , 03,	
1562	Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. 2014 , 7, 307-16	19
1561	Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response. 2014 , 5, 1770-8	29
1560	Factors associated with breast cancer mortality after local recurrence. 2014 , 21, e418-25	25
1559	Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?. 2014 , e32-6	10
1558	Triple-negative breast cancer is not associated with increased likelihood of nodal metastases. 2014 , 21, 4098-103	30
1557	Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype. 2014 , 148, 541-51	50
1556	Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer. 2014 , 203, 272-9	30
1555	Prognosis in very young women with triple-negative breast cancer: retrospective study of 216 cases. 2014 , 31, 222	12
1554	Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine. 2014 , 14, 98	15
1553	L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. 2014 , 14, 958	22

1552	Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?. 2014 , 16, 457	2
1551	Addition von Bevacizumab bei triplenegativem Mammakarzinom. 2014 , 17, 10-12	
1550	Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. 2014 , 14, 847	43
1549	Loco-Regional Therapy for Early and Advanced Breast Cancer in the Molecular Era. 2014 , 6, 267-274	
1548	Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer. 2014 , 13, 2501-14	34
1547	Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. 2014 , 2014, 492173	30
1546	Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. 2014 , 7, 866-870	7
1545	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. 2014 , 7, 203-15	69
1544	Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. 2014 , 106, djt376	62
1543	Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma. 2014 , 138, 175-81	8
1542	Impact of radiation therapy on survival in patients with triple-negative breast cancer. 2014 , 7, 548-552	37
1541	Histological Analysis of Γ Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. 2014 , 5, 632	15
1540	Standard of care and promising new agents for triple negative metastatic breast cancer. 2014 , 6, 2187-223	32
1539	Molecular markers for breast cancer: prediction on tumor behavior. 2014 , 2014, 513158	104
1538	Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. 2014 , 9, 1-11	32
1537	Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report. 2014 , 10, 42-46	
1536	Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India. 2014 , 10, 26-8	14
1535	Triple-negative breast cancer: An institutional analysis. 2014 , 51, 163-6	21

1534	GPER Function in Breast Cancer: An Overview. 2014 , 5, 66	71
1533	Computational analysis of mRNA expression profiles identifies the ITG family and PIK3R3 as crucial genes for regulating triple negative breast cancer cell migration. 2014 , 2014, 536591	12
1532	Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response. 2014 , 13, 1814-27	31
1531	Mammographic and clinicopathological features of triple-negative breast cancer. 2014 , 87, 20130496	18
1530	Intensive postoperative surveillance using chest CT and bone scan in patients with locally advanced breast cancer. 2014 , 20, 558-9	
1529	Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study. 2014 , 135, 669-81	12
1528	Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer. 2014 , 13, 2104-15	41
1527	A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. 2014 , 148, 489-99	31
1526	Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. 2014 , 3, 225-44	41
1525	Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. 2014 , 111, E5429-38	349
1524	Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. 2014 , 25, 618-623	21
1523	Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. 2014 , 16, R28	31
1522	Breast-conserving therapy for triple-negative breast cancer. 2014 , 149, 252-8	54
1521	Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression. 2014 , 290, 1221-9	11
1520	Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. 2014 , 148, 553-61	140
1519	Clinical Evaluation of Platinum Agents for the Treatment of Triple Negative Breast Cancer. 2014 , 6, 289-295	1
1518	Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer. 2014 , 14, 715	12
1517	Preferential, enhanced breast cancer cell migration on biomimetic electrospun nanofiber 'cell highways'. 2014 , 14, 825	41

1516	Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: mutation analysis. 2014 , 14, 14	20
1515	The treatment and survival of patients with triple negative breast cancer in a London population. 2014 , 3, 553	19
1514	Correlation of clinicopathologic parameters and immunohistochemical features of triple-negative invasive lobular carcinoma. 2014 , 22, e18-26	8
1513	Biopsychosocial predictors of psychological functioning among African American breast cancer survivors. 2014 , 32, 493-516	5
1512	Significance of serum vascular endothelial growth factor and cancer antigen 15.3 in patients with triple negative breast cancer. 2014 , 13, 60-67	7
1511	The prognostic importance of nuclear factor B and hypoxia-inducible factor 1β in relation to the breast cancer subtype and the overall survival. 2014 , 22, 464-70	6
1510	Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 413-24	12.9 46
1509	Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features. 2014 , 138, 37-43	34
1508	Breast cancer pathology, receptor status, and patterns of metastasis in a rural appalachian population. 2014 , 2014, 170634	12
1507	Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis. 2014 , 3, e968001	23
1506	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. 2014 , 348, g226	181
1505	Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. 2014 , 149, 125-9	63
1504	Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients. 2014 , 9, 421-7	5
1503	Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. 2014 , 2, 245-251	28
1502	High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. 2014 , 7, 1475-80	114
1501	FOXP3 transcription factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. 2014 , 2014, 341654	13
1500	Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer. 2014 , 14, 511-21	13
1499	Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. 2014 , 16, R36	55

1498	Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. 2014 , 141, 323-33	37
1497	How to identify patients with increased risk of breast cancer relapse?. 2014 , 22, 488-97	2
1496	Neoadjuvant chemotherapy in breast cancer: what questions remain?. 2014 , 8, 59-63	3
1495	Everolimus: a new hope for patients with breast cancer. 2014 , 30, 75-87	20
1494	E10. Current multidisciplinary management in breast cancer. 2014 , 50, S19-S21	
1493	Le cancer du sein triple-négatif. Le triple-négatif est fréquent chez les patientes mutées: comment ne pas le rater? Comment le caractériser? De manière plus générale, l'imagerie peut-elle orienter vers le diagnostic histologique?. 2014 , 24, 105-112	
1492	Expression of cancer stem cell markers in basal and penta-negative breast carcinomas—a study of a series of triple-negative tumors. 2014 , 210, 432-9	13
1491	Boswellia ovalifoliolata abrogates ROS mediated NF- κ B activation, causes apoptosis and chemosensitization in Triple Negative Breast Cancer cells. 2014 , 38, 58-70	22
1490	Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. 2014 , 27, 352-60	102
1489	Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. 2014 , 289, 141-7	29
1488	Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. 2014 , 40, 1-12	52
1487	INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells. 2014 , 35, 4469-77	11
1486	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. 2014 , 143, 385-92	43
1485	Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues. 2014 , 35, 4457-68	32
1484	Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. 2014 , 143, 57-68	25
1483	DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. 2014 , 143, 47-55	95
1482	Concomitant resistance and early-breast cancer: should we change treatment strategies?. 2014 , 33, 271-83	10
1481	Time to breast cancer relapse predicted by primary tumour characteristics, not lymph node involvement. 2014 , 38, 1668-75	7

1480	Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan. 2014 , 19, 852-62	17
1479	Reproductive risk factors and breast cancer subtypes: a review of the literature. 2014 , 144, 1-10	204
1478	Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy. 2014 , 21, 1209-14	34
1477	Tripelnegatives Mammakarzinom. 2014 , 9, 6-10	
1476	Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California. 2014 , 144, 625-34	46
1475	ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype. 2014 , 31, 864	32
1474	Predictive factors and patterns of recurrence in patients with triple negative breast cancer. 2014 , 21, 2165-71	33
1473	Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis. 2014 , 14, 57	26
1472	Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. 2014 , 14, 62	76
1471	Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. 2014 , 32, 14-24	37
1470	PKC β signaling promotes triple-negative breast cancer growth and metastasis. 2014 , 21, 1469-81	32
1469	Engineering mammary gland in vitro models for cancer diagnostics and therapy. 2014 , 11, 1971-81	8
1468	Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. 2014 , 32, 2309-23	67
1467	Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. 2014 , 18, 863-81	30
1466	Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. 2014 , 6, 88-100	29
1465	Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?. 2014 , 88, 57-64	33
1464	Tumorsphere assay provides more accurate prediction of in vivo responses to chemotherapeutics. 2014 , 36, 481-8	30
1463	Valeur pronostique des sous-types moléculaires et du Ki67 pour les cancers du sein indemnes d'envahissement ganglionnaire après mastectomie : expérience de l'institut Curie à l'hôpital René-Huguenin et revue de la littérature. 2014 , 18, 35-46	

1462	Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. 2014 , 31, 801	45
1461	Targeting multiple pathways in breast cancer. 2014 , 3, 87-101	0
1460	Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. 2014 , 232, 142-50	267
1459	Breast-Cancer Subtyping in Clinical Practice: Clinicopathologic Features and Outcomes. 2014 , 30, 260-264	1
1458	Whole blueberry powder inhibits metastasis of triple negative breast cancer in a xenograft mouse model through modulation of inflammatory cytokines. 2014 , 66, 242-8	27
1457	miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. 2014 , 8, 1690-702	58
1456	Emerging Prognostic and Predictive Biomarkers for Triple Negative Breast Cancer. 2014 , 6, 275-282	1
1455	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. 2014 , 27, 1212-22	163
1454	Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies. 2014 , 111, 2328-41	34
1453	Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer. 2014 , 90, 94-100	24
1452	Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome. 2014 , 148, 211-20	18
1451	Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. 2014 , 74, 5184-94	169
1450	MicroRNAs as regulatory elements in triple negative breast cancer. 2014 , 354, 1-4	34
1449	New strategies for triple-negative breast cancer--deciphering the heterogeneity. <i>Clinical Cancer Research</i> , 2014 , 20, 782-90	12.9 210
1448	Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. 2014 , 110, 1378-84	44
1447	Anti-tumor activity of novel bisoquinoline derivatives against breast cancers. 2014 , 24, 4850-3	3
1446	JCOG activities in geriatric oncology. 2014 , 5, S9	
1445	Triple negative breast cancer (TNBC) patients diagnosed at different age present similar clinicopathological features, but different treatment and prognosis in Chinese population. 2014 , 5, S9	

1444	Recruitment of circulating breast cancer cells is stimulated by radiotherapy. 2014 , 8, 402-9	49
1443	A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. 2014 , 8, 9925-40	117
1442	Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors. 2014 , 191, 90-97	71
1441	Induction of cell cycle arrest and apoptosis in caspase-3 deficient MCF-7 cells by <i>Dillenia suffruticosa</i> root extract via multiple signalling pathways. 2014 , 14, 197	29
1440	Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. 2014 , 13, 174	27
1439	Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients. 2014 , 7, 399	10
1438	The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China. 2014 , 19, 35	19
1437	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. 2014 , 16, 406	199
1436	Molecular classification of infiltrating breast cancer: toward personalized therapy. 2014 , 34, 1178-95	51
1435	Platinum-based chemotherapy in triple-negative advanced breast cancer. 2014 , 146, 567-72	26
1434	Circulating tumor cells in non-metastatic triple-negative breast cancer. 2014 , 147, 325-33	27
1433	The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster. 2014 , 146, 41-50	30
1432	Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. 2014 , 145, 593-604	67
1431	Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. 2014 , 146, 175-82	18
1430	PD-L1 expression in triple-negative breast cancer. 2014 , 2, 361-70	698
1429	Cdc20 and securin overexpression predict short-term breast cancer survival. 2014 , 110, 2905-13	91
1428	Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. 2014 , 21, 3780-6	53
1427	MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. 2014 , 12, 1216-24	24

1426	Triple-negative breast cancer: future prospects in diagnosis and management. 2014 , 31, 834	22
1425	COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients. 2014 , 31, 989	14
1424	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. 2014 , 14, 302	37
1423	Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF- κ B pathway. 2014 , 14, 96	44
1422	Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. 2014 , 12, 95	29
1421	Definition of PKC- β CDK6, and MET as therapeutic targets in triple-negative breast cancer. 2014 , 74, 4822-35	48
1420	Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells. 2014 , 8, 6372-81	283
1419	Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer. 2014 , 1843, 815-26	30
1418	Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors. 2014 , 45, 802-9	15
1417	Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis. 2014 , 19, 173-81	8
1416	Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. 2014 , 25, 611-618	267
1415	Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. 2014 , 21, 283-9	25
1414	The omics of triple-negative breast cancers. 2014 , 60, 122-33	44
1413	Axl receptor tyrosine kinase expression in breast cancer. 2014 , 67, 690-6	36
1412	Triple-negative breast carcinoma: current and emerging concepts. 2014 , 141, 462-77	119
1411	Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 3003-11	12.9 60
1410	GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β estradiol in triple-negative breast cancer cells. 2014 , 143, 392-403	57
1409	Nanomedicine for the treatment of triple-negative breast cancer. 2014 , 9, 561-4	12

1408	MicroRNA-200b targets protein kinase C β and suppresses triple-negative breast cancer metastasis. 2014 , 35, 2254-63	85
1407	Basal-like and triple-negative breast cancers: searching for positives among many negatives. 2014 , 23, 567-77	65
1406	Primary relapse site pattern in women with triple-negative breast cancer. 2014 , 210, 571-5	10
1405	Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library. 2014 , 21, 738-47	1
1404	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. 2014 , 33, 148-56	67
1403	Molecular Targets in Gynecologic Cancers. 2014 , 1-17	
1402	Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. 2014 , 12, 71-80	27
1401	Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. 2014 , 16, R70	25
1400	Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients. 2014 , 2, 845-850	19
1399	Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. 2014 , 32, 2230-6	22
1398	The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. 2014 , 44, 700-8	20
1397	Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer. 2014 , 7, 252-9	2
1396	Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer. 2014 , 44, 2025-33	26
1395	The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. 2014 , 34, 276-82	21
1394	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. 2015 , 16, 575	20
1393	Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis. 2015 , 10, 413-6	8
1392	Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. 2015 , 106, 1582-9	46
1391	Tumour Necrosis Factor- α Gene Polymorphism Is Associated with Metastasis in Patients with Triple Negative Breast Cancer. 2015 , 5, 10244	16

1390	Novel therapy for locally advanced triple-negative breast cancer. 2015 , 47, 1266-72	13
1389	Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis. 2015 , 3, 720-724	11
1388	Novel genes associated with lymph node metastasis in triple negative breast cancer. 2015 , 5, 15832	31
1387	Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. 2015 , 13, 947-52	11
1386	An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation. 2015 , e52672	8
1385	2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. 2014 , 4, 7095	21
1384	Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis. 2015 , 9, 2825-2832	7
1383	Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. 2015 , 33, 526-32	9
1382	High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. 2015 , 15, 986	13
1381	Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. 2015 , 4, 386	21
1380	Women with large (â7cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival. 2015 , 4, 9	6
1379	CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid. 2015 , 14, 129	36
1378	Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. 2015 , 17, 46	44
1377	Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. 2015 , 17, 124	151
1376	Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer. 2015 , 7, 104	25
1375	Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs. 2015 , 30, e200-7	22
1374	Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience. 2015 , 21, 627-33	34
1373	The expression and clinical significance of ribophorin II (RPN2) in human breast cancer. 2015 , 65, 301-8	17

1372	Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. 2015 , 7, 797-816	39
1371	Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes. 2015 , 22, 306-13	11
1370	Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. 2015 , 6, 1306-19	14
1369	Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. 2015 , 14, 4282-90	11
1368	Bioluminescence-activated deep-tissue photodynamic therapy of cancer. 2015 , 5, 805-17	48
1367	Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response. 2015 , 8, 3415-23	5
1366	CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. 2015 , 6, 25356-67	26
1365	Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). 2015 , 3, 519-43	13
1364	The role of taxanes in triple-negative breast cancer: literature review. 2015 , 9, 4303-18	79
1363	Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. 2015 , 10, e0132449	33
1362	Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population. 2015 , 10, e0140208	3
1361	Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer. 2015 , 10, e0142911	2
1360	A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. 2015 , 10, e0144712	29
1359	Triple Negative Breast Cancer in Pregnancy and Postpartum: Two Case Reports in Hispanic Women. 2015 , 2015, 856931	1
1358	Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. 2015 , 6, 16638-52	74
1357	Triple-negative breast cancer: molecular subtypes and new targets for therapy. 2015 , e31-9	83
1356	Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells. 2015 , 6, 30975-92	54
1355	Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation. 2015 , 6, 23383-98	25

1354	Biomarkers in triple negative breast cancer: A review. 2015 , 6, 252-63	65
1353	Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay. 2015 , 107,	37
1352	Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates. 2015 , 12, 1250-8	40
1351	Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage. 2015 , 112, 1461-70	52
1350	BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. 2015 , 9, 1528-38	45
1349	Triple-negative breast cancer: new perspectives for targeted therapies. 2015 , 8, 177-93	94
1348	Clinical Relevance of Multidrug-Resistance-Proteins (MRPs) for Anticancer Drug Resistance and Prognosis. 2015 , 27-52	9
1347	Relapse profile of early breast cancer according to immunohistochemical subtypes: guidance for patient's follow up?. 2015 , 7, 144-52	4
1346	Biological Subtypes of Breast Cancer. 2015 , 1-6	
1345	Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. 2015 , 25, 1172-81	25
1344	Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. 2015 , 25, 3314-21	26
1343	Mammographic tumour appearance and triple-negative breast cancer associated with long-term prognosis of breast cancer death: a Swedish Cohort Study. 2015 , 39, 200-8	9
1342	Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. 2015 , 15, 399	93
1341	Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. 2015 , 14, 1306-16	36
1340	The fate of chemoresistance in triple negative breast cancer (TNBC). 2015 , 3, 257-75	216
1339	Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy. 2015 , 24, 397-405	10
1338	Cytotoxic activity of ten algae from the Persian Gulf and Oman Sea on human breast cancer cell lines; MDA-MB-231, MCF-7, and T-47D. 2015 , 7, 133-7	9
1337	Triple Negative Breast Cancer: Nanosolutions for a Big Challenge. 2015 , 2, 1500053	27

1336	Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature. 2015 , 94, e1756	4
1335	Overview of Genetically Engineered Mouse Models of Breast Cancer Used in Translational Biology and Drug Development. 2015 , 70, 14.36.1-14.36.14	11
1334	Gene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast cancer progression. 2015 , 15, 473	24
1333	Unexpected features of breast cancer subtype. 2015 , 13, 249	2
1332	BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs. 2015 , 75, 1345-55	22
1331	Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis. 2015 , 89, 337-44	20
1330	Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. 2015 , 24, 1666-72	81
1329	Potential Therapeutic Targets in Triple Negative Breast Cancer. 2015 , 7, 215-223	1
1328	Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death. 2015 , 472, 287-95	15
1327	Transforming growth factor- β /insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer. 2015 , 12, 851-64	39
1326	M410, a combretastatin A4 analogue, disrupts microtubules and inhibits HIF-1 α in human breast cancer cells. 2015 , 34, 334-40	6
1325	The evolution of regional nodal irradiation in breast cancer. 2015 , 21, 32-41	8
1324	Breast Cancer: Epidemiology and Etiology. 2015 , 72, 333-8	342
1323	A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. 2015 , 136, 1976-84	14
1322	Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. 2015 , 24, 131-6	18
1321	The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. 2015 , 22, 874-82	74
1320	Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study. 2015 , 22, 2881-7	12
1319	Breast- and salivary gland-derived adenoid cystic carcinomas: potential post-transcriptional divergencies. A pilot study based on miRNA expression profiling of four cases and review of the potential relevance of the findings. 2015 , 21, 29-44	10

1318	Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. 2015 , 11, 823-34	2
1317	Resistance to Targeted ABC Transporters in Cancer. 2015 ,	3
1316	Glycoproteomic comparison of clinical triple-negative and luminal breast tumors. 2015 , 14, 1376-88	10
1315	Reduced risk of axillary lymphatic spread in triple-negative breast cancer. 2015 , 149, 229-36	24
1314	BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. 2015 , 36, 4243-52	27
1313	Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. 2015 , 6, 5899	118
1312	Overexpression of reactive oxygen species scavenger enzymes is associated with a good prognosis in triple-negative breast cancer. 2015 , 88, 9-17	10
1311	Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). 2015 , 10, 365-73	19
1310	Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting. 2015 , 37, 134-44	12
1309	Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma. 2015 , 32, 275	21
1308	Subtyping of triple-negative breast cancer: implications for therapy. 2015 , 121, 8-16	212
1307	Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. 2015 , 22, 82-9	88
1306	p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy. 2015 , 24, 294-7	18
1305	Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine. 2015 , 290, 3936-49	19
1304	Targeting a cell state common to triple-negative breast cancers. 2015 , 11, 789	17
1303	Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast. 2015 , 49, 19-25	14
1302	USP2 promotes cell migration and invasion in triple negative breast cancer cell lines. 2015 , 36, 5415-23	31
1301	(18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?. 2015 , 25, 2460-9	29

1300	Radiation therapy in the locoregional treatment of triple-negative breast cancer. 2015 , 16, e113-22	64
1299	The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. 2015 , 150, 389-94	49
1298	An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. 2015 , 75, 3246-54	29
1297	MRI kinetics with volumetric analysis in correlation with hormonal receptor subtypes and histologic grade of invasive breast cancers. 2015 , 204, W348-56	19
1296	An HDAC-Targeted Imaging Probe LBH589-Cy5.5 for Tumor Detection and Therapy Evaluation. 2015 , 12, 2469-76	19
1295	Milk derived colloid as a novel drug delivery carrier for breast cancer. 2015 , 16, 1184-93	2
1294	Targeted Therapies in Triple-Negative Breast Cancer. 2015 , 10, 159-66	44
1293	Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. 2015 , 112, E4600-9	142
1292	Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer. 2015 , 72, 4369-82	20
1291	Elevated TGF- β 1 and - β 2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells. 2015 , 75, 151-8	33
1290	The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. 2015 , 16, 1535-47	13
1289	Targeting delivery and deep penetration using multistage nanoparticles for triple-negative breast cancer. 2015 , 5, 64303-64317	31
1288	Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. 2015 , 6, 206-13	66
1287	CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers. 2015 , 16, 2412-7	27
1286	Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. 2015 , 34, 373-83	31
1285	Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 5460-8 ^{12.9}	34
1284	Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer. 2015 , 9, 149-152	22
1283	The triterpenoids of Hibiscus syriacus induce apoptosis and inhibit cell migration in breast cancer cells. 2015 , 15, 65	35

1282	Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting. 2015 , 127, 253-81	19
1281	An overview of triple negative breast cancer for surgical oncologists. 2015 , 24, 276-83	21
1280	Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer. 2015 , 16, 856-65	53
1279	Optimizing Adjuvant Taxanes in Early Breast Cancer. 2015 , 33, 2334-6	1
1278	Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. 2015 , 151, 619-27	43
1277	S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer. 2015 , 99, 180-7	13
1276	A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. 2015 , 16, 225-32	17
1275	Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. 2015 , 22, 2098-106	67
1274	Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. 2015 , 152, 183-191	49
1273	In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer. 2015 , 63, 58-69	78
1272	miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. 2015 , 36, 1051-60	60
1271	Biologic, demographic, and social factors affecting triple negative breast cancer outcomes. 2015 , 19, 62-7	7
1270	A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers. 2015 , 139, 612-7	28
1269	Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. 2015 , 112, 1751-9	97
1268	Clinical implication of leucine zipper/EF hand-containing transmembrane-1 overexpression in the prognosis of triple-negative breast cancer. 2015 , 98, 254-9	13
1267	Cell signaling events differentiate ER-negative subtypes from ER-positive breast cancer. 2015 , 32, 142	4
1266	Therapies for triple negative breast cancer. 2015 , 16, 983-98	60
1265	Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells. 2015 , 150, 487-99	18

1264	Retrospective analysis of metastatic behaviour of breast cancer subtypes. 2015 , 150, 547-57	104
1263	Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. 2015 , 15, 89	35
1262	Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review. 2015 , 15, 1	72
1261	High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. 2015 , 13, 7	13
1260	Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. 2015 , 17, 31	26
1259	Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience. 2015 , 4, 132	5
1258	Critical analysis of the potential for microRNA biomarkers in breast cancer management. 2015 , 7, 59-79	46
1257	Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer. 2015 , 22 Suppl 3, S552-8	37
1256	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. 2015 , 15, 195	78
1255	FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth. 2015 , 17, 47	29
1254	Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. 2015 , 14, 769-78	140
1253	Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. 2015 , 151, 281-94	49
1252	Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?. 2015 , 41, 547-53	31
1251	S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype. 2015 , 137, 2093-103	14
1250	New treatment strategies for patients with triple-negative breast cancer. 2015 , 27, 77-84	20
1249	Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer. 2015 , 130, 73-80	11
1248	Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study. 2015 , 26, 117-22	6
1247	APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer. 2015 , 36, 574-84	26

1246	Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. 2015 , 33, 2114-2125		53
1245	Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer. 2015 , 27, 1315-24		11
1244	Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. 2015 , 16, 436-46		175
1243	Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. 2015 , 15, 259-65		29
1242	MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer. 2015 , 116, 2061-73		25
1241	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2722-9	12.9	45
1240	Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers. 2015 , 36, 4793-9		13
1239	Copper(II) complexes of methyl 4-aryl-6-methyl-3,4-dihydropyrimidine-2(1H)-thione-5-carboxylates. Synthesis, characterization and activity in human breast cancer cells. 2015 , 438, 160-167		8
1238	Heat Shock Proteins in Triple-Negative Breast Cancer (TNBC) Treatment. 2015 , 129-149		1
1237	Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. 2015 , 526, 131-5		584
1236	Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers. 2015 , 38, 433-42		52
1235	Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. 2015 , 144, 713-21		26
1234	Better Together: Targeted Combination Therapies in Breast Cancer. 2015 , 42, 887-95		39
1233	Clinical and molecular complexity of breast cancer metastases. 2015 , 35, 85-95		86
1232	Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. 2015 , 14, 2850-63		28
1231	Heterogeneity between triple negative breast cancer cells due to differential activation of Wnt and PI3K/AKT pathways. 2015 , 339, 67-80		14
1230	Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis. 2015 , 205, 878-85		26
1229	Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate. 2015 , 12, 505-6		3

1228	Precision Molecular Pathology of Breast Cancer. 2015,	3
1227	Heat Shock Protein-Based Therapies. 2015,	4
1226	Disparities in breast cancer and african ancestry: a global perspective. 2015, 21, 133-9	41
1225	Microvascular proliferation in luminal A and basal-like breast cancer subtypes. 2015, 68, 891-7	16
1224	Clinical implications of molecular heterogeneity in triple negative breast cancer. 2015, 24 Suppl 2, S36-40	76
1223	Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. 2015, 4, e991228	11
1222	Does internal mammary node irradiation affect treatment outcome in clinical stage II-III breast cancer patients receiving neoadjuvant chemotherapy?. 2015, 152, 589-99	18
1221	Emerging Predictive Biomarkers of Response to Platinum Therapy in Triple-Negative Breast Cancer. 2015, 7, 224-231	
1220	The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer. 2015 , 467, 1070-5	14
1219	Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. 2015, 4, e168	24
1218	The Molecular Pathology of Chemoresistance During the Therapeutic Response in Breast Cancer. 2015, 291-307	1
1217	What common biomarkers characterize a triple-negative profile in breast cancer?. 2015, 63, 224-9	8
1216	Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. 2015, 24 Suppl 2, S132-5	20
1215	Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. 2015, 26, 1904-1910	50
1214	Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells. 2015, 414, 91-8	8
1213	Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?. 2015, 75, 5014-22	131
1212	Evaluating the utility of trefoil factor 1 as a mammary-specific immunostain compared and in conjunction with GATA-3 and mammaglobin in the distinction between carcinoma of breast and lung. 2015, 144, 444-51	2
1211	A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. 2015, 75, 4651-64	143

1210	CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015—Still in the Ballpark. <i>Clinical Cancer Research</i> , 2015 , 21, 3813-4	12.9	9
1209	Regional recurrence in the era of sentinel lymph node biopsy. 2015 , 210, 1155-60; discussion 1160-1		4
1208	Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. 2015 , 41, 35-45		82
1207	The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. 2015 , 34, 761-70		35
1206	Biochemical Roles of Eukaryotic Cell Surface Macromolecules. 2015 ,		4
1205	Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer. 2015 , 56, 1463-70		14
1204	Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression. 2015 , 19, 37-42		20
1203	Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. 2015 , 111, 198-202		7
1202	Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine. 2015 , 70, 1-10		37
1201	Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. 2015 , 136, 204-11		48
1200	β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer. 2015 , 22, 298-310		60
1199	Equal as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines. 2015 , 22, 382-90		14
1198	Current advances in biomarkers for targeted therapy in triple-negative breast cancer. 2016 , 8, 183-197		25
1197	Lx2-32c-loaded polymeric micelles with small size for intravenous drug delivery and their inhibitory effect on tumor growth and metastasis in clinically associated 4T1 murine breast cancer. 2016 , 11, 5457-5472		8
1196	Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer. 2016 , 7, 167-73		68
1195	Antibody Therapeutics in Oncology. 2016 , 02,		8
1194	The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer. 2016 , 12, 1500-1510		13
1193	Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. 2016 , 7, 27158-75		37

1192	Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy. 2016 , 57, 1192-8	15
1191	Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. 2016 , 7, 2309-2316	20
1190	Wortmannin as Targeted Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer. 2016 , 15, 95	
1189	Being Overweight or Obese Increases the Risk of Progression in Triple-Negative Breast Cancer after Surgical Resection. 2016 , 31, 886-91	15
1188	A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. 2016 , 7, 12344-58	28
1187	Luminal B breast cancer: patterns of recurrence and clinical outcome. 2016 , 7, 65024-65033	42
1186	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. 2016 , 35, 34-42	55
1185	Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. 2016 , 7, 69903-69915	40
1184	Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo. 2016 , 7, 67223-67234	59
1183	Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. 2016 , 7, 1747-1754	7
1182	Tratamiento de cáncer de seno y farmacogenética. 2016 , 18,	
1181	Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. 2016 , 6, 533-44	82
1180	Overexpression of seven in absentia homolog 2 protein in human breast cancer tissues is associated with the promotion of tumor cell malignant behavior in in vitro. 2016 , 36, 1301-12	4
1179	Molecular subtypes of breast carcinoma in Saudi Arabia. A retrospective study. 2016 , 37, 506-12	25
1178	β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer. 2016 , 17,	31
1177	Optimized Method for Untargeted Metabolomics Analysis of MDA-MB-231 Breast Cancer Cells. 2016 , 6,	12
1176	Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women. 2016 , 5, 756	8
1175	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. 2016 , 11, e0157368	590

1174	BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. 2016 , 11, e0167016	20
1173	The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. 2016 , 17, 566	61
1172	Triple-negative breast cancer: treatment challenges and solutions. 2016 , 8, 93-107	146
1171	Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. 2016 , 55, 915-924	13
1170	Potential role of targeted therapies in the treatment of triple-negative breast cancer. 2016 , 27, 147-55	46
1169	Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience. 2016 , 22, 510-9	5
1168	The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca(2+) flux from the endoplasmic reticulum to mitochondria. 2016 , 23, 1702-16	24
1167	MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer. 2016 , 55, 768-77	23
1166	Emerging Opportunities for c-MET Visualization in the Clinic. 2016 , 57, 663-4	4
1165	Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. 2016 , 11, 2320-2326	4
1164	PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. 2016 , 5, 805	44
1163	Triple negative breast cancer: Deciphering the biology and heterogeneity. 2016 , 18, 105-114	14
1162	Association between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: a protocol for a systematic review. 2016 , 5, 133	3
1161	Depletion of SENP1 suppresses the proliferation and invasion of triple-negative breast cancer cells. 2016 , 36, 2071-8	20
1160	STC-1 expression is upregulated through an Akt/NF- κ B-dependent pathway in triple-negative breast cancer cells. 2016 , 36, 1717-22	14
1159	Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. 2016 , 6, 28888	28
1158	Current challenges of metastatic breast cancer. 2016 , 35, 495-514	42
1157	Agonists and knockdown of estrogen receptor α differentially affect invasion of triple-negative breast cancer cells in vitro. 2016 , 16, 951	35

1156	Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features. 2016 , 16, 68	9
1155	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. 2016 , 14, 173	77
1154	The relationship between nuclear factor (NF)- κ B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. 2016 , 6, 31804	35
1153	Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers. 2016 , 40, 1109-16	43
1152	Two-faced activity of RNF8: What "twists" it from a genome guardian to a cancer facilitator?. 2016 , 3, e1242454	4
1151	Triple-negative breast carcinoma: Heterogeneity in immunophenotypes and pharmacokinetic behavior. 2016 , 58, 55-63	6
1150	Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. 2016 , 15, 2265-74	34
1149	Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. 2016 , 16, 256-61	16
1148	Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. 2016 , 101, 20-31	58
1147	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 5864-5875	12.9 64
1146	"Triple negative breast cancer": Translational research and the (re)assembling of diseases in post-genomic medicine. 2016 , 59, 20-34	11
1145	Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. 2016 , 16, 335-343	142
1144	EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features. 2016 , 11, 41	25
1143	The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients. 2016 , 47, 12-21	27
1142	Understanding the cancer cell phenotype beyond the limitations of current omics analyses. 2016 , 283, 54-73	31
1141	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. 2016 , 29, 476-88	67
1140	Triple-negative breast carcinoma: heterogeneity in immunophenotypes and pharmacokinetic behavior. 2016 , 58, 55-63	6
1139	Her2-neu score as a prognostic factor for Her outcome in patients with triple-negative breast cancer. 2016 , 142, 1369-76	7

1138	Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer. 2016 , 13, 1833-42	54
1137	Binding of anterior gradient 2 and estrogen receptor- β Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer. 2016 , 377, 32-43	18
1136	Post-adjuvant chemotherapy for triple-negative breast cancer. 2016 , 90, 74-5	1
1135	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. 2016 , 156, 507-515	22
1134	The incidence of bone metastasis after early-stage breast cancer in Canada. 2016 , 156, 587-595	37
1133	GATA-3 expression is not associated with complete pathological response in triple negative breast cancer patients treated with neoadjuvant chemotherapy. 2016 , 212, 539-44	4
1132	Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer. 2016 , 108,	17
1131	Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. 2016 , 18, 33	106
1130	Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. 2016 , 157, 109-16	25
1129	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. 2016 , 34, 2460-7	867
1128	Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells. 2016 , 187, 195-204	18
1127	Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?. 2016 , 8, 209-29	22
1126	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. 2016 , 157, 157-65	36
1125	Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. 2016 , 157, 77-90	39
1124	Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. 2016 , 29, 810-23	22
1123	Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. 2016 , 23, 783-796	24
1122	Optimization of Poli(e-caprolactone) Scaffolds Suitable for 3D Cancer Cell Culture. 2016 , 49, 61-66	9
1121	Breast Cancer. 2016 , 1313-1328.e15	1

1120	Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. 2016 , 146, 496-502	66
1119	βp63 Expression induces loss of cell adhesion in triple-negative breast cancer cells. 2016 , 16, 782	9
1118	Mechanisms underlying effect of the mycotoxin cytochalasin B on induction of cytotoxicity, modulation of cell cycle, Ca homeostasis and ROS production in human breast cells. 2016 , 370, 1-19	15
1117	Overexpression of miR-509 Increases Apoptosis and Inhibits Invasion via Suppression of Tumor Necrosis Factor-α in Triple-Negative Breast Cancer Hs578T Cells. 2016 , 24, 233-8	17
1116	Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. 2016 , 140, 806-14	70
1115	Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer. 2016 , 30, 1817-1823	14
1114	Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells. 2016 , 104, 3031-3044	14
1113	Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. 2016 , 165, 170-180	12
1112	Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. 2016 , 36, 755-62	2
1111	Interstitial Release of Cisplatin from Triggerable Liposomes Enhances Efficacy against Triple Negative Breast Cancer Solid Tumor Analogues. 2016 , 13, 3224-33	13
1110	Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities. 2016 , 5, 558-73	15
1109	Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. 2016 , 5, 1983-8	33
1108	A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein. 2016 , 139, 916-27	22
1107	Preclinical Models for Studying Breast Cancer. 2016 , 183-209	
1106	PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion. 2016 , 380, 505-512	30
1105	PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells. 2016 , 16, 540	14
1104	The hedgehog pathway in triple-negative breast cancer. 2016 , 5, 2989-3006	71
1103	Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. 2016 , 15, 2598-2608	41

1102	The Pathobiology of Breast Cancer. 2016 ,	4
1101	Rhus coriaria suppresses angiogenesis, metastasis and tumor growth of breast cancer through inhibition of STAT3, NF κ B and nitric oxide pathways. 2016 , 6, 21144	45
1100	Tryptophan hydroxylase 1 and 5-HT receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. 2016 , 15, 75	50
1099	Screening and characterization of novel specific peptides targeting MDA-MB-231 claudin-low breast carcinoma by computer-aided phage display methodologies. 2016 , 16, 881	6
1098	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. 2016 , 2, 16036	89
1097	Elevated IL-1 β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone. 2016 , 258, 126-33	26
1096	The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. 2016 , 63, 1021-33	50
1095	Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications. 2016 , 37, 14479-14499	5
1094	Targeting the androgen receptor in triple-negative breast cancer. 2016 , 40, 141-150	50
1093	Triple-Negative/Basal-Like Breast Carcinomas. 2016 , 431-443	
1092	Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones. 2016 , 24, 5921-5928	18
1091	Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. 2016 , 50, 129-141	52
1090	[Non-metastatic triple-negative breast cancer in 2016: Definitions and management]. 2016 , 44, 492-504	2
1089	miR-9 and miR-200 Regulate PDGFR β Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. 2016 , 76, 5562-72	67
1088	Biology and Management of Patients With Triple-Negative Breast Cancer. 2016 , 21, 1050-62	131
1087	A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. 2016 , 6, 37003	9
1086	Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ER α inhibition. 2016 , 590, 4606-4616	23
1085	A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. 2016 , 1, 15015	25

1084	Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England. 2016 , 115, 1408-1415	26
1083	Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. 2016 , 6, 30091	15
1082	High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. 2016 , 16, 673	17
1081	Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer. 2016 , 38, 1003-14	45
1080	Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells. 2016 , 86, 153-161	5
1079	The Apocrine Profile of Triple-negative Breast Carcinomas in Patients Aged 45 Years or Younger: favorable but rare features. 2016 , 38, 512-517	3
1078	CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer. 2016 , 6, 35383	36
1077	Phototheranostics of CD44-positive cell populations in triple negative breast cancer. 2016 , 6, 27871	47
1076	Trends of triple negative breast cancer research (2007-2015): A bibliometric study. 2016 , 95, e5427	17
1075	Polypyrrole-based nanotheranostics for activatable fluorescence imaging and chemo/photothermal dual therapy of triple-negative breast cancer. 2016 , 27, 185102	21
1074	Fat grafting for breast cancer patients: From basic science to clinical studies. 2016 , 42, 1088-102	13
1073	Breast Cancer Prevention and Treatment. 2016 ,	4
1072	Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar. 2016 , 25, 763-768	
1071	Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. 2016 , 157, 475-88	29
1070	Impact of central obesity on prognostic outcome of triple negative breast cancer in Chinese women. 2016 , 5, 594	22
1069	Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4687-97	12.9 36
1068	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. 2016 , 16, 138	28
1067	Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer. 2016 , 23, 3524-3530	10

1066	Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer. 2016 , 477, 461-6	48
1065	Surgery and radiation therapy of triple-negative breast cancers: From biology to clinics. 2016 , 28, 148-55	15
1064	Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis. 2016 , 19, 419-30	8
1063	Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study. 2016 , 156, 465-472	37
1062	In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. 2016 , 15, 1823-33	20
1061	Radiotherapy in Patients 70 Years and Older With Triple-Negative Breast Cancer. 2016 , 16, e99-e106	7
1060	The Nuclear Receptor, ROR α Regulates Pathways Necessary for Breast Cancer Metastasis. 2016 , 6, 59-72	29
1059	miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells. 2016 , 18, 40	30
1058	Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model. 2016 , 15, 46	30
1057	Bisphenol A Increases the Migration and Invasion of Triple-Negative Breast Cancer Cells via Oestrogen-related Receptor Gamma. 2016 , 119, 389-95	28
1056	Clinicopathological features and prognosis of triple-negative breast cancer: a comparison between younger (. 2016 , 25, 1065-1075	9
1055	Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. 2016 , 49, 11-21	35
1054	The Role of mTOR Inhibitors in Breast Cancer. 2016 , 67-92	
1053	Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1653-62	12.9 53
1052	CD73-adenosine: a next-generation target in immuno-oncology. 2016 , 8, 145-63	82
1051	Methylsulfonylmethane inhibits HER2 expression through STAT5b in breast cancer cells. 2016 , 48, 836-42	11
1050	Anticipatory activation of the unfolded protein response by epidermal growth factor is required for immediate early gene expression and cell proliferation. 2016 , 422, 31-41	21
1049	Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature. 2016 , 34, e21-4	51

1048	Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. 2016 , 16, 39-50	9
1047	Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer. 2016 , 104, 31-7	29
1046	Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. 2016 , 33, 179-85	18
1045	Desacetyl nimbinene inhibits breast cancer growth and metastasis through reactive oxygen species mediated mechanisms. 2016 , 37, 6527-37	7
1044	c-Met PET Imaging Detects Early-Stage Locoregional Recurrence of Basal-Like Breast Cancer. 2016 , 57, 765-70	17
1043	The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking. 2016 , 343, 73-81	18
1042	N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. 2016 , 16, 23-30	31
1041	Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF- β expression. 2016 , 37, 11397-407	17
1040	Multi-walled nanotubes for cellular reprogramming of cancer. 2016 , 12, 955-963	2
1039	Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. 2016 , 4, 390-9	66
1038	Post-mastectomy Radiation: Should Subtype Factor into the Decision?. 2016 , 23, 2462-70	4
1037	Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. 2016 , 34, 809-819	50
1036	Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. 2016 , 16, 541-51	3
1035	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. 2016 , 15, 593-607	39
1034	The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer. 2016 , 7, 149-64	48
1033	Latent class model characterization of neighborhood socioeconomic status. 2016 , 27, 445-52	12
1032	Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells. 2016 , 28, 506-515	54
1031	Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. 2016 , 16, 143	42

1030	Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. 2016 , 76, 2105-14	128
1029	Immunohistochemistry for Triple-Negative Breast Cancer. 2016 , 1406, 39-51	2
1028	A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. 2016 , 39, 265-77	52
1027	High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer. 2016 , 382, 77-85	24
1026	SSBP1 Suppresses TGF β -Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling. 2016 , 76, 952-64	42
1025	Nanomedicine for Treatment of Lung Cancer. 2016 , 890, 137-47	46
1024	Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. 2016 ,	1
1023	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. 2016 , 76, 927-39	103
1022	Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. 2016 , 47-48, 15-23	52
1021	SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. 2016 , 37, 4743-53	24
1020	Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged . 2016 , 18, 82-7	29
1019	Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients. 2016 , 57, 802-8	14
1018	Androgen receptor expression as a prognostic and predictive marker in triple-negative breast cancer patientsPeer review under responsibility of Alexandria University Faculty of Medicine.View all notesAvailable online 30 October 2015View all notes. 2016 , 52, 131-140	5
1017	Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRI-1 MRI-Including Screening Study. <i>Clinical Cancer Research</i> , 2016 , 22, 895-904	12.9 25
1016	MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells. 2016 , 37, 4991-9	24
1015	Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis. 2016 , 23, 876-885	35
1014	An overview of triple-negative breast cancer. 2016 , 293, 247-69	268
1013	ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. 2016 , 35, 3201-8	290

1012	Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models. <i>Clinical Cancer Research</i> , 2016 , 22, 923-34	12.9	28
1011	Understanding genistein in cancer: The "good" and the "bad" effects: A review. 2016 , 196, 589-600		152
1010	KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2. 2016 , 35, 2040-51		86
1009	cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. 2017 , 36, 512-524		16
1008	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017 , 23, 649-657	12.9	75
1007	Cytokeratin 17 Expression is Associated With Poor Prognosis in Gallbladder Adenocarcinoma. 2017 , 25, 346-350		11
1006	Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1 α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. 2017 , 232, 192-201		16
1005	Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21 expression. 2017 , 32, 434-444		80
1004	Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. 2017 , 6, 547-554		7
1003	Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. 2017 , 36, 3553-3561		11
1002	Imaging Surveillance After Primary Breast Cancer Treatment. 2017 , 208, 676-686		36
1001	Loss of monocyte chemoattractant protein-1 expression delays mammary tumorigenesis and reduces localized inflammation in the C3(1)/SV40Tag triple negative breast cancer model. 2017 , 18, 85-93		12
1000	Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. 2017 , 6, e1274479		8
999	Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study. 2017 , 6, 526-536		14
998	Higher densities of Foxp3 regulatory T cells are associated with better prognosis in triple-negative breast cancer. 2017 , 163, 21-35		65
997	Quantifying tumour vascularity in non-luminal breast cancers. 2017 , 70, 766-774		6
996	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. <i>Clinical Cancer Research</i> , 2017 , 23, 4035-4045	12.9	79
995	Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. 2017 , 26, 463-479		29

994	Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer. 2017 , 485, 693-697	8
993	Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. 2017 , 18, 205-213	47
992	Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. 2017 , 19, 6	39
991	Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils. 2017 , 5, 234-247	41
990	Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles. 2017 , 24, R81-R97	16
989	PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer. 2017 , 7, 42319	13
988	Adhesion of ligand-conjugated biosynthesized magnetite nanoparticles to triple negative breast cancer cells. 2017 , 68, 276-286	12
987	Selective in vivo metabolic cell-labeling-mediated cancer targeting. 2017 , 13, 415-424	188
986	Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. 2017 , 6, e1305531	35
985	Aptamer-mediated impairment of EGFR-integrin $\alpha 3$ complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. 2017 , 7, 46659	50
984	Application of surface enhanced Raman spectroscopy as a diagnostic system for hypersialylated metastatic cancers. 2017 , 134, 143-153	17
983	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. 2017 , 164, 57-67	19
982	Imbalance in leptin-adiponectin levels and leptin receptor expression as chief contributors to triple negative breast cancer progression in Northeast India. 2017 , 621, 51-58	29
981	Expression of Axl and its prognostic significance in human breast cancer. 2017 , 13, 621-628	16
980	FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer. 2017 , 79, 1205-1213	16
979	Exploiting Homologous Recombination Deficiency in TNBC. 2017 , 9, 52-59	
978	Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study. 2017 , 34, 53-57	6
977	Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. 2017 , 19, 52	40

976	Triple-negative breast cancer in the elderly: Prognosis and treatment. 2017 , 23, 630-637	21
975	The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. 2017 , 470, 51-55	80
974	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. 2017 , 116, 1425-1435	50
973	Patterns of Initial Recurrence in Completely Resected Papillary Thyroid Carcinoma. 2017 , 27, 908-914	37
972	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. 2017 , 77, 3834-3845	58
971	Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors. 2017 , 15, 973-983	14
970	Risque de r�cidive locale en fonction de la classification mol�culaire, exemple du cancer du sein. 2017 , 19, 85-91	1
969	Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. 2017 , 3, 402-409	14
968	An Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer. 2017 , 16, 1967-1978	16
967	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. 2017 , 77, 1313-1336	25
966	Novel therapeutic strategies in the treatment of triple-negative breast cancer. 2017 , 9, 493-511	44
965	Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. 2017 , 77, 3455-3466	45
964	Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells. 2017 , 7, 2022	26
963	Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. 2017 , 22, 1086-1093	53
962	The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. 2017 , 28, 2256-2263	54
961	Synthesis and biological evaluation of 2-(3,4-dimethoxyphenyl)-6-(2-[F]fluoroethoxy)benzothiazole ([F]FEDBT) for PET imaging of breast cancer. 2017 , 27, 3460-3463	7
960	Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. 2017 , 8, 15507	36
959	TRPV4 plays a role in breast cancer cell migration via Ca-dependent activation of AKT and downregulation of E-cadherin cell cortex protein. 2017 , 6, e338	59

958	Centrosome amplification: a suspect in breast cancer and racial disparities. 2017 , 24, T47-T64	12
957	MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1. 2017 , 117, 78-88	74
956	Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells. 2017 , 40, 746-759	19
955	The regulatory role of miRNAs on VDR in breast cancer. 2017 , 8, 232-241	13
954	MIF Family Cytokines in Innate Immunity and Homeostasis. 2017 ,	2
953	Breast cancer biomarkers at Niger delta university hospital: Comparisons with national and international trends and clinical significance. 2017 , 24, 191-196	3
952	Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an variant. 2017 , 3,	17
951	Risk factors and state-of-the-art indications for boost irradiation in invasive breast carcinoma. 2017 , 16, 552-564	17
950	Adenoid Cystic Carcinoma of the Breast. 2017 , 357-363	
949	Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model. 2017 , 7, 43961	14
948	Low-dose aspirin use and survival in breast cancer patients: A nationwide cohort study. 2017 , 48, 158	1
947	Germline Mutations in Triple-Negative Breast Cancer. 2017 , 12, 15-19	32
946	Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. 2017 , 389, 2430-2442	394
945	Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. 2017 , 161, 549-556	92
944	Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. 2017 , 28, 754-760	65
943	Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. 2017 , 161, 463-471	24
942	Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. 2017 , 22, 665-680	123
941	Perfusion Parameters on Breast Dynamic Contrast-Enhanced MRI Are Associated With Disease-Specific Survival in Patients With Triple-Negative Breast Cancer. 2017 , 208, 687-694	8

940	Surveillance of women with a personal history of breast cancer by tumour subtype. 2017 , 72, 266.e1-266.e6	0
939	Immunization against HIF-1 β inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 3396-3404	12.9 21
938	Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. 2017 , 241, 511-521	2
937	Gold nanorod embedded large-pore mesoporous organosilica nanospheres for gene and photothermal cooperative therapy of triple negative breast cancer. 2017 , 9, 1466-1474	34
936	The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer. 2017 , 43, 2047-2061	25
935	Co-activation of Hedgehog and Wnt signaling pathways is associated with poor outcomes in triple negative breast cancer. 2017 , 14, 5285-5292	18
934	MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1. 2017 , 7, 13996	42
933	Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy. 2017 , 14, 4551-4559	20
932	Breast cancer in the 21st century: From early detection to new therapies. 2017 , 59, 368-379	32
931	Triple-negative breast cancer and the potential for targeted therapy. 2017 , 18, 1595-1609	100
930	Autophagy-related molecules, light chain 3B, p62, and beclin 1, as prognostic markers in triple-negative breast cancer. 2017 , 37, 8-16	2
929	Targeting triple negative breast cancer with histone deacetylase inhibitors. 2017 , 26, 1199-1206	38
928	Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy. 2017 , 14, 3978-3986	46
927	How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. 2017 , 2, e000208	33
926	Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China. 2017 , 96, e8155	1
925	Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells. 2017 , 60, 9275-9289	23
924	Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. 2017 , 7, 13856	203
923	Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo. 2017 , 95, 18-24	72

922	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. 2017 , 32, 1-15	76
921	Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer. 2017 , 95, 922-928	88
920	MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer. 2017 , 14, 4805-4811	21
919	MicroRNA signature in the chemoprevention of functionally-enriched stem and progenitor pools (FESPP) by Active Hexose Correlated Compound (AHCC). 2017 , 18, 765-774	3
918	A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1. 2017 , 19, 1260-1273	72
917	Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines. 2017 , 17, 569-583	1
916	T-cadherin is associated with prognosis in triple-negative breast cancer. 2017 , 14, 2975-2981	2
915	Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance. 2017 , 14, 5039-5045	31
914	Repositioning of proton pump inhibitors in cancer therapy. 2017 , 80, 925-937	35
913	Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. 2017 , 62, 257-272	39
912	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. 2017 , 60, 53-59	17
911	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. 2017 , 3, 29	27
910	PIM1: a promising target in patients with triple-negative breast cancer. 2017 , 34, 142	20
909	Lycorine inhibits the growth and metastasis of breast cancer through the blockage of STAT3 signaling pathway. 2017 , 49, 771-779	20
908	Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome. 2017 , 67, 404-413	17
907	Breast cancer neoplastic seeding in the setting of image-guided needle biopsies of the breast. 2017 , 166, 29-39	15
906	Prognostic value of IMP3 expression as a determinant of chemosensitivity in triple-negative breast cancer. 2017 , 213, 1160-1165	5
905	STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance. 2017 , 24, 415-426	30

904	Breast cancer in the 21st century: from early detection to new therapies. 2017 , 59, 368-379	60
903	Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER β -negative Breast Cancers to Tamoxifen through ER β Reexpression. 2017 , 15, 1491-1502	9
902	Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. 2017 , 51, 781-790	27
901	Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants. 2017 , 166, 351-365	34
900	Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer. 2017 , 166, 407-419	6
899	Local therapy for triple-negative breast cancer: a comprehensive review. 2017 , 13, 1721-1730	8
898	PPAR γ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers. 2017 , 16, 2528-2542	22
897	Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study. 2017 , 84, 34-43	14
896	Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations. 2017 , 209, 920-928	35
895	Triple negative breast cancer and immunoglobulin A nephropathy: A case report and literature review. 2018 , 15, 979-983	1
894	Resistance to Targeted Therapies in Breast Cancer. 2017 ,	
893	EGFR Resistance. 2017 , 103-116	
892	Long-term prognosis of young breast cancer patients (≥ 40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. 2017 , 7, e017842	7
891	Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis. 2017 , 96, e8557	7
890	Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer. 2017 , 43, 418-435.e13	34
889	Hypoxia-induced reactive oxygen species mediate N-cadherin and SERPINE1 expression, EGFR signalling and motility in MDA-MB-468 breast cancer cells. 2017 , 7, 15140	71
888	EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. 2017 , 7, 15654	29
887	Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration. 2017 , 7, 14976	18

886	Androgen Receptor-Targeted Therapy for Breast Cancer. 2017 , 9, 242-250	0
885	MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer. 2018 , 105, 75-85	24
884	A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. 2017 , 10, 988-997	14
883	Randomized Clinical Trials on Breast Cancer in Nigeria and Other Developing Countries: Challenges and Constraints. 2017 , 123-159	2
882	Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. 2017 , 24, 3116-3123	12
881	Directing the Self-assembly of Tumour Spheroids by Bioprinting Cellular Heterogeneous Models within Alginate/Gelatin Hydrogels. 2017 , 7, 4575	65
880	Perioperative Inflammation as Triggering Origin of Metastasis Development. 2017 ,	1
879	Epidemiological Study of Triple-Negative Breast Cancer Patients in North Indian Population: a Hospital-Based Study. 2017 , 8, 279-283	
878	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. 2017 , 3, 17	27
877	Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. 2017 , 15, 4	11
876	Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. 2017 , 24, 698-704	24
875	A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). 2017 , 19, 616-624	3
874	Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells. 2017 , 56, 1383-1394	10
873	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. 2017 , 22, 25-32	56
872	Breast carcinoma with an Oncotype Dx recurrence score . 2017 , 123, 131-137	14
871	Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK. 2017 , 56, 849-862	21
870	Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. 2017 , 13, 403-410	46
869	Adaptive immunity programmes in breast cancer. 2017 , 150, 25-34	29

868	Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation. 2017 , 17, 55-60	11
867	Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. 2017 , 161, 279-287	178
866	Versatile Nanodelivery Platform to Maximize siRNA Combination Therapy. 2017 , 17, 1600294	8
865	A novel chalcone-based molecule, BDP inhibits MDA-MB-231 triple-negative breast cancer cell growth by suppressing Hsp90 function. 2017 , 38, 2343-2350	10
864	Prognostic significance of expression of epithelial-mesenchymal transition driver brachyury in breast cancer and its association with subtype and characteristics. 2018 , 15, 1037-1045	2
863	Resultados oncológicos de la cirugía oncológica: seguimiento a largo plazo de pacientes tratados en un instituto oncológico de Latinoamérica. Un análisis de cohortes. 2017 , 30, 170-178	1
862	Triple-negative breast cancer and its association with obesity. 2017 , 7, 935-942	22
861	Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling. 2018 , 15, 3017-3023	7
860	MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor E124. 2017 , 8, 19455-19466	51
859	Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer. 2017 , 8, 29668-29678	31
858	Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials. 2017 , 38, 18-23	3
857	Quercetin induces apoptosis and cell cycle arrest in triple-negative breast cancer cells through modulation of Foxo3a activity. 2017 , 21, 205-213	70
856	Triple negative breast cancer: the kiss of death. 2017 , 8, 46652-46662	95
855	Role of nestin expression in angiogenesis and breast cancer progression. 2018 , 52, 527-535	5
854	Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. 2017 , 8, 2026-2032	18
853	Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review. 2017 , 10, 2009-2016	3
852	STAT3/NF- κ B-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer. 2017 , 7, 647-663	54
851	Imaging Surveillance for Survivors of Breast Cancer: Correlation between Cancer Characteristics and Method of Detection. 2017 , 20, 192-197	1

850	PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer. 2017 , 22,	7
849	Electrospinning PCL Scaffolds Manufacture for Three-Dimensional Breast Cancer Cell Culture. 2017 , 9,	38
848	Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer. 2017 , 22, 1549-1580	7
847	AR Signaling in Breast Cancer. 2017 , 9,	57
846	Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair. 2017 , 18,	5
845	Ror2 Signaling and Its Relevance in Breast Cancer Progression. 2017 , 7, 135	27
844	Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial. 2017 , 21, 83-89	5
843	Ribosomal protein S3 regulates XIAP expression independently of the NF- κ B pathway in breast cancer cells. 2017 , 38, 3205-3210	17
842	Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer. 2017 , 13, 505-517	25
841	Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine. 2017 , 12, 7763-7776	25
840	Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. 2017 , 12, e0182786	40
839	Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts. 2017 , 12, e0183254	24
838	Stromal Fibroblasts from the Interface Zone of Triple Negative Breast Carcinomas Induced Epithelial-Mesenchymal Transition and its Inhibition by Emodin. 2017 , 12, e0164661	10
837	Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer. 2017 , 12, e0171683	80
836	Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. 2017 , 17, 727	21
835	Immunohistochemical staining of leptin is associated with grade, stage, lymph node involvement, recurrence, and hormone receptor phenotypes in breast cancer. 2017 , 17, 105	14
834	Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. 2017 , 19, 90	18
833	Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities. 2017 , 5, 6	78

832	Cellular inhibitor of apoptosis protein 2 promotes the epithelial-mesenchymal transition in triple-negative breast cancer cells through activation of the AKT signaling pathway. 2017 , 8, 78781-78795	7
831	Triple Negative Breast Cancer: A Single Centre Experience. 2017 , 10,	
830	Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. 2017 , 8, 75617-75626	9
829	No association between triple-negative breast cancer and prognosis of patients receiving breast-conserving treatment. 2017 , 14, 7862-7872	2
828	The role of p53 in cancer drug resistance and targeted chemotherapy. 2017 , 8, 8921-8946	285
827	Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model. 2017 , 8, 178-189	18
826	Targeting the androgen receptor in triple-negative breast cancer: current perspectives. 2017 , 10, 4675-4685	38
825	Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. 2017 , 20, 347-355	8
824	RNA interference-mediated silencing of ppGalNAc-T1 and ppGalNAc-T2 inhibits invasion and increases chemosensitivity potentially by reducing terminal α ,3 sialylation and MMP14 expression in triple-negative breast cancer cells. 2017 , 15, 3724-3734	2
823	The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. 2017 , 11, 324	19
822	Salicylate α -phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells. 2017 , 8, 29823-29832	12
821	Mammography and ultrasound effective features in differentiating basal-like and normal-like subtypes of triple negative breast cancer. 2017 , 8, 79670-79679	2
820	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. 2017 , 35, 2141-2148	177
819	Novel Targeted Agents and Immunotherapy in Breast Cancer. 2017 , 37, 65-75	5
818	Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. 2017 , 29, 237-252	75
817	PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. 2018 , 52, 755-767	12
816	I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53. 2018 , 99, 220-226	14
815	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 2605-2615	12.9 30

814	A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. 2018 , 9, 832	22
813	Transcriptomic and epigenetic analysis of breast cancer stem cells. 2018 , 10, 765-783	15
812	Decreasing cytokeratin 17 expression in head and neck cancer predicts nodal metastasis and poor prognosis: The first evidence. 2018 , 43, 1010-1018	4
811	High and low molecular weight hyaluronic acid-coated gold nanobipyramids for photothermal therapy.. 2018 , 8, 9023-9030	14
810	Clinicopathological and Ultrasonic Features of Triple-Negative Breast Cancers: A Comparison with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancers. 2018 , 44, 1124-1132	13
809	The role of curcuma rhizoma-sparganii rhizoma medicated serum in epithelial-mesenchymal transition in the triple negative breast cancer: Pharmacological role of CR-SR in the TBNC. 2018 , 99, 340-345	8
808	Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer. 2018 , 20, 1448-1454	9
807	Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. 2018 , 19, 22	41
806	Experience with eribulin in triple-negative metastatic breast cancer: case studies. 2018 , 14, 13-20	2
805	Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins. 2018 , 17, 539-551	19
804	[Presentation and outcome of breast cancer under 40 years - A French monocentric study]. 2018 , 46, 105-111	0
803	"Stealth and Fully-Laden" Drug Carriers: Self-Assembled Nanogels Encapsulated with Epigallocatechin Gallate and siRNA for Drug-Resistant Breast Cancer Therapy. 2018 , 10, 9938-9948	35
802	Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands. 2018 , 10, 4258-4266	50
801	Mitotically-Associated lncRNA (MANCR) Affects Genomic Stability and Cell Division in Aggressive Breast Cancer. 2018 , 16, 587-598	45
800	Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. 2018 , 8, 1952	99
799	Pathologic Evaluation of Triple-Negative Breast Cancer. 2018 , 1-22	2
798	EHMT2 is a metastasis regulator in breast cancer. 2018 , 496, 758-762	23
797	Triple-Negative Breast Cancer: Clinical Features. 2018 , 23-32	3

796	Imaging of Triple-Negative Breast Cancer. 2018 , 41-54	
795	Surgical Management of Triple-Negative Breast Cancer. 2018 , 55-69	1
794	Radiation Therapy for Triple-Negative Breast Cancer. 2018 , 71-82	
793	Optimizing Adjuvant and Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. 2018 , 83-94	1
792	Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. 2018 , 9, 82-94	18
791	Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy. 2018 , 10, 7022-7030	17
790	Berberine Suppresses Cell Motility Through Downregulation of TGF- β 1 in Triple Negative Breast Cancer Cells. 2018 , 45, 795-807	38
789	Injectable Hexapeptide Hydrogel for Localized Chemotherapy Prevents Breast Cancer Recurrence. 2018 , 10, 6972-6981	58
788	Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer. 2018 , 41, 1049-1057	10
787	Individualizing the Approach to the Older Woman with Triple-Negative Breast Cancer. 2018 , 159-177	
786	Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells. 2018 , 9, 42	24
785	Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1. 2018 , 8, 1138	16
784	The combined pN stage and breast cancer subtypes in breast cancer: a better discriminator of outcome can be used to refine the 8th AJCC staging manual. 2018 , 25, 315-324	5
783	Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and F-FDG-PET. 2018 , 25, 334-342	4
782	Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. 2018 , 168, 625-630	55
781	Clinically Established Prognostic Factors in Breast Cancer. 2018 , 250-257.e3	2
780	Locoregional Recurrence After Mastectomy. 2018 , 808-813.e3	
779	Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer. 2018 , 885-906.e8	1

778	Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer. 2018 , 28, 420-424	4
777	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. 2018 , 579-594	1
776	Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer. 2018 , 26, 1-5	1
775	Assessing N -hydroxy-L-arginine applicability as a novel ethnic specific estrogen-negative breast cancer marker. 2018 , 50, 373-382	6
774	Hypoxia Inducible Factors Modify Collagen I Fibers in MDA-MB-231 Triple Negative Breast Cancer Xenografts. 2018 , 20, 131-139	15
773	Genotypes and haplotypes of ABCB1 contribute to TAC chemotherapy response in Malaysian triple negative breast cancer patients. 2018 , 16, 21-27	0
772	Triple-Negative Breast Cancer. 2018 ,	
771	Management of Metastatic Triple-Negative Breast Cancer. 2018 , 95-116	
770	Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review. 2018 , 20, 1145-1156	15
769	CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells. 2018 , 363, 65-72	17
768	Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial. 2018 , 96, 111-117	6
767	Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer. 2018 , 18, e1229-e1235	13
766	Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. 2018 , 29, 1056-1062	92
765	Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: A large population-based analysis. 2018 , 44, 420-428	30
764	Functional Isolation of Tumor-Initiating Cells using Microfluidic-Based Migration Identifies Phosphatidylserine Decarboxylase as a Key Regulator. 2018 , 8, 244	22
763	A Synthetic Binder of Breast Cancer Stem Cells. 2018 , 24, 3694-3698	3
762	Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy. 2018 , 37, 4	10
761	A Forkhead Box Protein C2 Inhibitor: Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis. 2018 , 19, 1359-1364	9

760	The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. 2018 , 67, 34-44	46
759	Breast cancer in an 18-year-old female: A fatal case report and literature review. 2018 , 19, 543-548	2
758	Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-VE axis. 2018 , 215, 1679-1692	34
757	Triple negative breast cancer: new therapeutic approaches and BRCA status. 2018 , 126, 371-379	28
756	miR-30a inhibits epithelial-mesenchymal transition and metastasis in triple-negative breast cancer by targeting ROR1. 2018 , 39, 2635-2643	18
755	Dual Receptor Targeting Cell Penetrating Peptide Modified Liposome for Glioma and Breast Cancer Postoperative Recurrence Therapy. 2018 , 35, 130	16
754	Regulation of AMPK-related glycolipid metabolism imbalances redox homeostasis and inhibits anchorage independent growth in human breast cancer cells. 2018 , 17, 180-191	23
753	Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. 2018 , 22, 547-557	45
752	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. 2018 , 170, 351-360	5
751	Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer. 2018 , 59, 1056-1062	11
750	Camnospermenone A, B and C, three new cytotoxic alkyl-hydroxycyclohexenones from <i>Camnosperma zeylanica</i> Thwaites leaves. 2018 , 24, 114-119	1
749	Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer. 2018 , 170, 221-234	16
748	Yellow fever vaccine 17D administered to healthy women aged between 40 and 54 years halves breast cancer risk: an observational study. 2018 , 27, 303-309	5
747	Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients. 2018 , 24, 297-308	6
746	PerPAS: Topology-Based Single Sample Pathway Analysis Method. 2018 , 15, 1022-1027	5
745	Enterotoxin B Anchored Exosome Induces Endoplasmic Reticulum Mediated Apoptosis in the Breast Cancer Cell Line. 2018 , 24, 99-104	
744	Triple Negative Breast Cancer: Experience from a North Indian Tertiary Care Center. 2018 , 80, 474-478	1
743	Alarming Burden of Triple-Negative Breast Cancer in India. 2018 , 18, e393-e399	63

742	Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. 2018 , 18, e401-e405	10
741	Breast Cancer Epidemiology in Gulf Cooperation Council Countries: A Regional and International Comparison. 2018 , 18, e381-e392	30
740	Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer. 2018 , 142, 844-853	7
739	Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. 2018 , 31, 288-298	31
738	Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney. 2018 , 48, 567-572	2
737	Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes. 2018 , 18, e123-e133	18
736	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. 2018 , 167, 89-99	48
735	Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. 2018 , 66, 294-309	20
734	Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. 2018 , 118, 17-23	39
733	Diffusion-weighted imaging features of breast tumours and the surrounding stroma reflect intrinsic heterogeneous characteristics of molecular subtypes in breast cancer. 2018 , 31, e3869	18
732	Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells. 2018 , 41, 229-242	12
731	Advanced glycation end products promote triple negative breast cancer cells via ERK and NF- κ B pathway. 2018 , 495, 2195-2201	16
730	IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. 2018 , 415, 30-39	25
729	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. 2018 , 167, 671-686	345
728	Targeting bromodomain and extraterminal proteins in breast cancer. 2018 , 129, 156-176	26
727	Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. 2018 , 293, 1120-1137	39
726	Triple negative breast cancer in Asia: An insider's view. 2018 , 62, 29-38	108
725	Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. 2018 , 62, 110-122	198

724	Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?. 2018 , 27, 141-153	51
723	Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. 2018 , 14, 32-39	63
722	Role of Plasma D-Dimer Levels in Breast Cancer Patients and Its Correlation with Clinical and Histopathological Stage. 2018 , 9, 307-311	7
721	GPER1 promotes estrogen receptor negative breast cancer cell migration and invasion via non-genomic activation of c-Src/NF- κ B/focal adhesion kinase cascade. 2018 , 1, 45-55	1
720	Epidemiological, Clinical, and Histopathological Features of Breast Cancer in Haiti. 2018 , 4, 1-9	9
719	Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?. 2018 , 14, 281-289	8
718	Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives. 2018 , 4, 1-20	4
717	Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. 2014 , 15, 10577-83	18
716	Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand. 2014 , 15, 1187-92	13
715	Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy. 2014 , 15, 2577-81	13
714	Radio-sensitization by Piper longumine of human breast adenoma MDA-MB-231 cells in vitro. 2014 , 15, 3211-7	19
713	Clinicopathologic characteristics of breast cancer in Jamaica. 2014 , 15, 3319-22	11
712	Locally advanced breast cancer in Jamaica: prevalence, disease characteristics and response to preoperative therapy. 2014 , 15, 3323-6	7
711	Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer. 2015 , 16, 8397-403	5
710	Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival. 2015 , 16, 1643-9	2
709	Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes. 2015 , 16, 3229-32	28
708	Recent Progress in Triple Negative Breast Cancer Research. 2016 , 17, 1595-608	26
707	Current approaches in treatment of triple-negative breast cancer. 2015 , 12, 106-16	273

706	Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments. 2018 , 6, e4340	9
705	Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer. 2020 , 8, e9975	5
704	Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. 2016 , 8, e924	37
703	Immunohistochemical profile and morphology in triple - negative breast cancers. 2013 , 7, 1361-5	22
702	A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Women. 2015 , 9, PC01-4	9
701	Clinicopathological Study of Triple Negative Breast Cancers. 2016 , 10, EC05-EC09	3
700	Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer. 2021 , 14,	5
699	RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer. 2021 , 13,	2
698	Molecular characterization of triple negative breast cancer formaldehyde-fixed paraffin-embedded samples by data-independent acquisition proteomics. 2021 , e2100110	0
697	Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures. 2021 , 13,	3
696	Periostin Exon-21 Antibody Neutralization of Triple-Negative Breast Cancer Cell-Derived Periostin Regulates Tumor-Associated Macrophage Polarization and Angiogenesis. 2021 , 13,	0
695	Breast cancer growth and proliferation is suppressed by the mitochondrial targeted furazano[3,4-b]pyrazine BAM15. 2021 , 9, 36	1
694	Obesity Modulates the Gut Microbiome in Triple-Negative Breast Cancer. 2021 , 13,	2
693	Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. 2021 , 21, 1303-1311	1
692	Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population-based study. 2021 , 10, 8662-8672	1
691	Disease-Free Survival after Breast Conservation Therapy vs. Mastectomy of Patients with T1/2 Breast Cancer and No Lymph Node Metastases: Our Experience. 2021 , 11, 9800	0
690	Prediction of Breast Cancer Recurrence Using a Deep Convolutional Neural Network Without Region-of-Interest Labeling. 2021 , 11, 734015	0
689	Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis. 2021 , 190, 549-558	2

- 688 A novel jamming phase diagram links tumor invasion to non-equilibrium phase separation. **2021**, 24, 103252 8
- 687 Neoadjuvant in situ immunomodulation enhances systemic antitumor immunity against highly metastatic tumors. **2021**, 2 2
- 686 Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer. **2021**, 64, 17051-17062 2
- 685 Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer. **2021**, 14, 101235 1
- 684 Clinicopathologic Characteristics and Prognosis of Early Stage Triple Negative Breast Cancer: Comparison with Non-triple Negative Group. **2009**, 77, 37 2
- 683 Chemotherapy for Metastatic Breast Cancer. **2009**, 1233-1261 1
- 682 Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer. **2009**, 3, 39-47
- 681 Adjuvant Systemic Therapy. **2010**, 741-753
- 680 References. **2011**, 249-347
- 679 Successful Treatment of Recurrent Triple-Negative Breast Cancer with Combination of Targeted Therapies. **2011**, 02, 372-376
- 678 Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer. **2011**, 050-066
- 677 Molecular subtypes and emerging therapeutic opportunities. **2011**, 24-36
- 676 Understanding Triple-Negative Breast Cancer. **2013**, 97-116
- 675 Effects of Nodal Status and Extent of Surgery on Survival in Triple Negative Breast Cancer.
- 674 Encyclopedia of Cancer. **2014**, 1-3
- 673 Liver Metastases from Breast Cancer. **2015**, 15-31
- 672 Protein Expression and Codon 72 Polymorphism of TP53 Gene in Triple Negative Breast Cancer. **2014**, 57, 895-899
- 671 Triple-Negative Breast Cancer among Ghanaian Women Seen at Korle-Bu Teaching Hospital. **2015**, 4, 1-5

- 670 Probability Distributions for Effectiveness Parameters. **2015**, 87-103
- 669 Triple Negative Breast Cancer: Molecular Classification, Prognostic Markers and Targeted Therapies. **2015**, 3,
- 668 SU BRCA 1 IR 2 MUTACIJOMIS SUSIJUSIO KRTIES VĖD RADIOLOGINIAI IR MORFOLOGINIAI POŪMIAI: TRUMPA LITERATROS APŪVALGA IR PATIRTIS NVI. **2015**, 21, 528-534
- 667 Early Stage Triple Negative Breast Cancer Has Significantly Better Outcomes than More Advanced Disease: A Single Centre Retrospective Review. **2016**, 07, 665-674 1
- 666 A Case of Rapidly Progressive and Disseminated Meningeal Carcinomatosis from Breast Cancer. **2016**, 77, 768-772
- 665 BRCA Patient Population. **2016**, 49-57
- 664 Introduction. **2016**, 1-12
- 663 Clinical characteristics of triple negative breast cancer in Egyptian women: a hospital-based experience. **2016**, 4, 426
- 662 CD74, MIF and Breast Tumorigenesis: Insights from Recent Large-Scale Tumour Genomics and Proteomics Studies. **2017**, 43-57
- 661 Triple-Negative Breast Cancer. **2017**, 4658-4660
- 660 Prediction of Molecular Mechanisms of Breast Cancer Metastasis.
- 659 Breast Cancer Treatment Protocols: Systematic Review of the Last 35 Years. **2017**, 6, 57-102
- 658 Triple Negative Breast Cancer in Iranian Women: Clinical Profile and Survival Study. **2017**, 10, 4
- 657 Association between Molecular Subtypes and Survival in Patients with Breast Cancer. **2017**, 6, 135-141
- 656 Hyperinsulineamia as Risk Factor for Early Breast Cancer Recurrence Linked to Hormone Receptors and Human Epidermal Growth Factor Receptor 2. **2017**, 4, 1-4 1
- 655 Langzeitfolgen einer Krebserkrankung âWie ein Job dabei helfen kann, diese zu beherrschen. **2018**, 67-96
- 654 Folate receptor- β expression in triple-negative and non-triple-negative invasive breast carcinoma. **2017**, 37, 268-273
- 653 Value of FOXP3 expression in prediction of neoadjuvant chemotherapy effect in triple-negative breast cancer. **2017**, 37, 257-267

- 652 Evolution of an intratumoral ecology susceptible to successive treatment in breast cancer xenografts.
- 651 Immunotherapy in the drug treatment of patients with triple-negative metastatic breast cancer. **2018**, 7, 60
- 650 Immunohistochemical Study of CK 5/6 in Benign and Malignant Breast Lesions. **2018**, 4, 95-102
- 649 Rare non-synonymous germline mutations systematically define the risk of triple negative breast cancer.
- 648 Downregulation of RIP140 in triple-negative breast cancer inhibits the growth and proliferation of cancer cells. **2018**, 15, 8784-8788 1
- 647 Quantitative nano-bio-imaging of cancer disease state. **2018**, 33, 179-189
- 646 COMPARISON OF CLINICO-PATHOLOGICAL FEATURES AND PROGNOSIS OF TRIPLE-NEGATIVE AND NON-TRIPLE-NEGATIVE FEMALE BREAST CANCER PATIENTS. **2018**, 7, 3412-3418
- 645 Comparison of Different Dynamic Contrast Enhanced-Magnetic Resonance Imaging Descriptors and Clinical Findings Among Breast Cancer Subtypes Determined Based on Molecular Assessment. **2018**, In Press, 0
- 644 Molecular-biological characteristics of triple negative breast cancer. **2018**, 17, 23-27
- 643 Novel Approaches to Immunotherapy in Triple Negative Breast Cancer. **2018**, In Press, 1
- 642 Clinical Advances in the Treatment of Metastatic Triple Negative Breast Cancer. **2019**, 09, 871-876
- 641 Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer.
- 640 Post-Mastectomy Adjuvant Radiotherapy (PMRT). **2019**, 187-198
- 639 Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy.. **2019**, 2, 877-884
- 638 Breast Cancer Receptors and Targeting Strategies. **2019**, 79-108 0
- 637 Breast Cancer With Relevance for Heavy Metals, Mycotoxines, and Pesticides. **2019**, 152-192
- 636 Clinical and Cyto-Morphological Characterization of Triple Negative Breast Cancer. **2019**, 36, 84-88 0
- 635 Prognostic value of primary tumor surgery in stage IV breast cancer patients with different metastatic burdens: a propensity score-matched and population-based study.. **2019**, 8, 614-625

- 634 Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women. **2019**, 11, e4963 4
- 633 STAT3 and GR cooperate to drive basal-like triple negative breast cancer gene expression and proliferation.
- 632 HISTOMORPHOLOGY AND IMMUNOHISTOCHEMICAL SURROGATE MOLECULAR PROFILE OF CARCINOMA BREAST- A ONE-YEAR STUDY. **2019**, 6, 2351-2355
- 631 Integrating ensemble systems biology feature selection and bimodal deep neural network for breast cancer prognosis prediction.
- 630 A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment.
- 629 A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment.
- 628 Negatif meme kanserlerinin klinik ve demografik verileri-tek merkez deneyimi. 478-488
- 627 Histological Changes of Feline Mammary Carcinoma Treated by NPe6 HVJ-E PDT. **2020**, 40, 403-407
- 626 Independent factors FOR poor prognosis in young patients with stage I-III breast cancer. **2020**, 59, 242-251 3
- 625 Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer. **2020**, 4-21 0
- 624 Prevalence of metabolic disorders in obese triple negative breast cancer patients.
- 623 Prognostic values of EDNRB in triple-negative breast cancer. **2020**, 20, 149 2
- 622 Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer. **2020**, 16, 276-281 1
- 621 Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. **2021**, 11, 742139 0
- 620 Assessment of Digital Pathology Imaging Biomarkers Associated with Breast Cancer Histologic Grade.. **2021**, 28, 4298-4316 1
- 619 Chick Embryo Experimental Platform for Micrometastases Research in a 3D Tissue Engineering Model: Cancer Biology, Drug Development, and Nanotechnology Applications. **2021**, 9, 0
- 618 Metabolic and lipidomic characterization of radioresistant MDA-MB-231 human breast cancer cells to investigate potential therapeutic targets. **2022**, 208, 114449 1
- 617 Cetuximab-anchored gold nanorod mediated photothermal ablation of breast cancer cell in spheroid model embedded with tumor associated macrophage. **2021**, 106, 177-177 1

616	QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation. 2021 , 22,	0
615	Cancer-associated fibroblast-derived LRRC15 promotes the migration and invasion of triple-negative breast cancer cells via Wnt/ β -catenin signalling pathway regulation. 2022 , 25,	2
614	Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. 2020 , 11, 216-222	1
613	PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients. 2021 , 16, 523-531	2
612	Olaparib in the metastatic HER2-negative breast cancer setting. 2020 , 22-30	
611	A Mechanistic Investigation on the Anticancer Properties of SYA013, a Homopiperazine Analogue of Haloperidol with Activity against Triple Negative Breast Cancer Cells. 2020 , 5, 32907-32918	1
610	Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer. 2020 , 12, 1293-1302	
609	The potential role of cofilin-1 in promoting triple negative breast cancer (TNBC) metastasis via the extracellular vesicles (EVs). 2021 , 15, 101247	1
608	Association of CD4+ CD25+ FOXP3+ regulatory T-cells and human papilloma virus infection in Egyptian Women with breast cancer.	
607	Impact of MRI Screening on High-Risk Patient Outcome. 2020 , 201-221	
606	Intrinsic subtyping of breast cancer and its relevance with clinico-pathological features and outcomes in patients from North India: a single center experience. 2020 , 9, 164	0
605	The Roles of Ultrasound-Based Radiomics In Precision Diagnosis and Treatment of Different Cancers: A Literature Review. 2020 , 4, 291	
604	Histo- and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China: Evidences on necessity of histological subtyping and grading. 2020 , 32, 580-595	2
603	Evaluation of Prognostic Factors in Triple Negative Breast Cancer Patients with Emphasis on Angiogenesis. 2020 , 12, 107-117	1
602	Investigating Potential Drug Repurposing for Triple Negative Breast Cancer. 2020 , 15, 242-252	
601	Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation. 2021 ,	0
600	A Novel Prognostic Model Based on the Serum Iron Level for Patients With Early-Stage Triple-Negative Breast Cancer. 2021 , 9, 777215	
599	CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer. 2021 ,	0

598	The role of ferroptosis-related genes for overall survival prediction in breast cancer. 2021 , 35, e24094	2
597	Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms. 2021 , 13,	0
596	Clinicopathological and Imaging Features Predictive of Clinical Outcome in Metaplastic Breast Cancer. 2020 , 16, 729-738	0
595	Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy. 2020 , 016-018	
594	XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. 2020 , 9, 1219	0
593	Functional Exploration of Copy Number Alterations in a Drosophila Model of Triple Negative Breast Cancer.	
592	Molecular characterization of triple negative breast cancer formaldehyde-fixed paraffin-embedded samples by data-independent acquisition proteomics.	
591	Understanding and treating triple-negative breast cancer. 2008 , 22, 1233-9; discussion 1239-40, 1243	167
590	Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. 2010 , 3, 328-37	61
589	Technology as a force for improved diagnosis and treatment of breast disease. 2010 , 53, 268-77	18
588	Breast cancer in Kumasi, Ghana. 2012 , 46, 8-13	42
587	Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. 2012 , 5, 806-13	36
586	Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study. 2013 , 4, 235-49	7
585	Expression of metabolism-related proteins in triple-negative breast cancer. 2014 , 7, 301-12	11
584	Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer. 2013 , 1, 3-7	13
583	S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. 2014 , 6, 361-76	30
582	Prognostic value of different amounts of cancer stem cells in different molecular subtypes of breast cancer. 2012 , 1, 20-4	3
581	Expression of ALDH1 and TGF β in benign and malignant breast tumors and their prognostic implications. 2014 , 7, 4173-83	6

580	Relation between radiographic BI-RADS scores and triple negativity in patients with ductal carcinomas. 2014 , 7, 2334-8	1
579	Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. 2014 , 26, 550-7	3
578	WWOX suppresses KLF5 expression and breast cancer cell growth. 2014 , 26, 511-6	1
577	Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells. 2015 , 8, 4378-87	23
576	Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. 2015 , 7, 1009-20	28
575	Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine. 2015 , 5, 2330-43	17
574	Association between hormone receptors and HER-2/neu is age-related. 2015 , 8, 8472-9	3
573	Clinicopathological classification and traditional prognostic indicators of breast cancer. 2015 , 8, 8500-5	14
572	Survival Analysis of Breast Cancer Patients after Surgery with an Intermediate Event: Application of Illness-Death Model. 2015 , 44, 1677-84	6
571	Antibody Therapeutics in Oncology. 2016 , 2,	9
570	Breed- and age-related differences in canine mammary tumors. 2016 , 80, 146-55	4
569	Pathological Characteristics of Triple-Negative Breast Cancer at Main Referral Teaching Hospital, April 2014 to April 2015, Tehran, Iran. 2016 , 10, 200-205	4
568	Data Driven Approach to Burden of Treatment Measurement: A Study of Patients with Breast Cancer. 2016 , 2016, 1756-1763	7
567	Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report from Cancer Institute of Iran. 2017 , 11, 37-42	3
566	Epidemiologic and clinicopathologic evaluation of patients with breast cancer referred to Ghaem Hospital from 2005 to 2014. 2015 , 8, 184-189	
565	Triple Negative Breast Cancer at the University Hospital Mohammed VI âDujda. 2017 , 18, 195-200	2
564	Descriptive study of triple negative breast cancer in Eastern Algeria. 2018 , 29, 45	2
563	PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer. 2019 , 10, 3667-3680	4

562	RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3/PTEN pathway. 2019 , 9, 1583-1606	5
561	Epithelial cell adhesion molecule and epithelial-mesenchymal transition are associated with vasculogenic mimicry, poor prognosis, and metastasis of triple negative breast cancer. 2019 , 12, 1678-1689	12
560	Clinical characteristics and prognostic analysis of ipsilateral supraclavicular lymph node metastases in breast cancer patients: a retrospective study. 2019 , 12, 3526-3534	3
559	Trifluridine selectively inhibits cell growth and induces cell apoptosis of triple-negative breast cancer. 2020 , 10, 507-522	4
558	Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. 2020 , 10, 648-661	15
557	Role of F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography in the Evaluation of Early Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Triple-Negative Breast Cancer. 2020 , 35, 105-109	
556	[Preparation of warangalone-loaded liposomes and its inhibitory effect on breast cancer cells]. 2020 , 40, 876-883	
555	Pharmaceutical Advances and Proteomics Researches. 2019 , 18, 51-67	1
554	A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC. 2019 , 1, 1-8	
553	Uncoupling tumor necrosis factor- α and interleukin-10 at tumor immune microenvironment of breast cancer through miR-17-5p/MALAT-1/H19 circuit. 2022 , 46, 769-783	2
552	Fatty acid synthase as a feasible biomarker for triple negative breast cancer stem cell subpopulation cultured on electrospun scaffolds. 2021 , 12, 100155	1
551	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.. 2021 , 11, 769280	3
550	Development of a Prognostic Model Based on the Identification of EMT-Related lncRNAs in Triple-Negative Breast Cancer. 2021 , 2021, 9219961	0
549	Suppression of breast cancer progression by FBXL16 via oxygen-independent regulation of HIF1 β stability. 2021 , 37, 109996	1
548	Hybrid genetic model with ANOVA for predicting breast neoplasm using METABRIC gene data. 2021 ,	
547	Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer. 2021 , 39, 14	2
546	Impact of BRCA mutations and hormone receptor status on reproductive potential in breast cancer patients undergoing fertility preservation. 2021 , 1-4	2
545	Immunohistochemical Markers in Breast Cancer: A Cross-Sectional Study on Triple-Negative Breast Cancer in a Rural Tertiary Care Hospital.. 2021 , 13, e19486	1

544	Classes of therapeutics to amplify the immune response. 2021 , 1	0
543	A novel panel of blood-based microRNAs capable of discrimination between benign breast disease and breast cancer at early stages. 2021 , 1-10	0
542	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.. 2021 , 2, 514-530	3
541	Association Between Contrast-Enhanced Ultrasound Characteristics and Molecular Subtypes of Breast Cancer. 2021 ,	1
540	Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer. 2021 , 11, 766248	2
539	FOXC1. 2021 ,	0
538	High miR-3609 expression is associated with better prognosis in TNBC based on mining using systematic integrated public sequencing data.. 2022 , 23, 54	
537	Modeling Tumor: Lymphatic Interactions in Lymphatic Metastasis of Triple Negative Breast Cancer. 2021 , 13,	
536	Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells. 2021 , 121259	3
535	Identification of Potential Long Non-Coding RNA Candidates that Contribute to Triple-Negative Breast Cancer in Humans through Computational Approach. 2021 , 22,	1
534	Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer. 2021 , 11,	2
533	Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer.. 2021 , 9, 770115	1
532	lncRNA prostate cancer-associated transcript 18 upregulates activating transcription factor 7 to prevent metastasis of triple-negative breast cancer via sponging miR-103a-3p. 2021 ,	3
531	Long non-coding RNA anti-differentiation non-coding RNA affects proliferation, invasion, and migration of breast cancer cells by targeting miR-331. 2021 , 12, 12236-12245	
530	Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers. 2021 , 13,	7
529	Tyrosine kinase inhibitors in breast cancer (Review).. 2022 , 23, 114	4
528	Recent advances in targeted nanotherapeutic approaches for breast cancer management. 2021 , 16, 2605-26312	
527	Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. 2021 , 168, 103530	0

526	Elevated mRNA expression levels of inflammation-related genes in triple-negative breast cancer: A pilot study from North East India. 2021 , 1, 105	
525	Radiotherapy and Radiosensitization in Breast Cancer: Molecular Targets and Clinical Applications. 2021 , 169, 103566	0
524	Exosomes in triple negative breast cancer: From bench to bedside.. 2021 , 527, 1-9	2
523	Dual antisense oligonucleotide targeting miR-21/miR-155 synergize photodynamic therapy to treat triple-negative breast cancer and inhibit metastasis.. 2021 , 146, 112564	1
522	Intramammary edema of invasive breast cancers on MRI T-weighted fat suppression sequence: Correlation with molecular subtypes and clinical-pathologic prognostic factors.. 2022 , 83, 87-92	
521	Germline and Somatic Mutations in Archived Breast Cancer Specimens of Different Subtypes. 2021 , 55, 354-362	
520	RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts.	
519	Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [F]FDG PET/CT in Early Triple-Negative Breast Cancer.. 2022 , 14,	1
518	Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.. 2022 , 23,	11
517	Targeting transforming growth factor- β by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer.. 2022 , 1	0
516	IKBKE phosphorylates and stabilizes Snail to promote breast cancer invasion and metastasis.. 2022 ,	0
515	Recent progress of macrophage vesicle-based drug delivery systems.. 2022 , 1	1
514	Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.. 2022 , 192, 163	0
513	Triple-negative Breast Cancer (TNBC) and Its Luminal Androgen Receptor (LAR) Subtype: A Clinicopathologic Review of Cases in a University Hospital in Northwestern Nigeria.. 2022 , 25, 97-104	1
512	A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.. 2022 , 191, 599	2
511	Non- Early-Onset Breast Cancer in Young Women.. 2022 , 42, 5-22	1
510	Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.. 2022 , 17, e0262650	2
509	A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer.. 2021 , 11, 759952	0

508	MR imaging guided iron-based nanoenzyme for synergistic Ferroptosis&Starvation therapy in triple negative breast cancer. 2022 , 3, 159-167	2
507	Nucleolar and Coiled-Body Phosphoprotein 1 Is Associated With Stemness and Represents a Potential Therapeutic Target in Triple-Negative Breast Cancer.. 2022 , 12, 731528	
506	ZMIZ2 promotes the development of triple-receptor negative breast cancer.. 2022 , 22, 52	0
505	Identification of Five Cytotoxicity-Related Genes Involved in the Progression of Triple-Negative Breast Cancer.. 2021 , 12, 723477	2
504	Who's Who? Discrimination of Human Breast Cancer Cell Lines by Raman and FTIR Microspectroscopy.. 2022 , 14,	1
503	Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence.. 2022 , 9, 836417	11
502	Tumor microenvironment-related multigene prognostic prediction model for breast cancer.. 2022 , 14,	1
501	Estrogen receptor α (ER α)-mediated upregulation of hsa_circ_0000732 promotes tumor progression via sponging microRNA-1184 in triple-negative breast cancer (TNBC).. 2022 , 71, 255	1
500	Breast cancer recurrence: factors impacting occurrence and survival.. 2022 , 1	1
499	Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells.. 2022 , 819, 146246	0
498	Prognosis of triple-negative breast cancer associated with pregnancy: A propensity score-matched analysis from the French CALG (Cancer Associ~ la Grossesse) network.. 2022 , 61, 168-174	1
497	STAT3/HIF1A and EMT specific transcription factors regulated genes: Novel predictors of breast cancer metastasis.. 2022 , 818, 146245	0
496	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.. 2022 , 236, 108108	4
495	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.. 2022 , 10,	0
494	Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer.. 2022 ,	0
493	Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.. 2022 , 14, e21970	2
492	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.. 2022 ,	1
491	Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.. 2022 , 1	0

490	Association between fatty acid synthase and adipophilin expression in triple-negative breast cancer.. 2022 , 16, 80	0
489	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.. 2022 , 386, 556-567	29
488	Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.. 2022 , 21, 45	8
487	Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis.. 2022 , 13, 791	2
486	Evaluation of BRCA1/2 gene mutations in patients with high-risk breast and/or ovarian cancer in Turkey. 2022 ,	
485	MALAT-1/p53/miR-155/miR-146a ceRNA circuit tuned by methoxylated quercetin glycoside alters immunogenic and oncogenic profiles of breast cancer.. 2022 , 477, 1281	1
484	Alternagin-C, an alpha2beta1 integrin ligand, attenuates collagen-based adhesion, stimulating the metastasis suppressor 1 expression in triple-negative breast tumor cells.. 2022 ,	
483	HLA Class II Histocompatibility Antigen α Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer.. 2021 , 13,	0
482	A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.. 2021 , 13, eabj5070	4
481	SEN1 promotes triple-negative breast cancer invasion and metastasis via enhancing CSN5 transcription mediated by GATA1 deSUMOylation.. 2022 , 18, 2186-2201	0
480	Analysis of single-cell RNA-sequencing data identifies a hypoxic tumor subpopulation associated with poor prognosis in triple-negative breast cancer. 2022 , 19, 5793-5812	0
479	Mixed effects and mechanisms of cannabinoids for triple-negative breast cancer treatment. 2022 , 637-654	
478	Pattern of Failure and Treatment Results in Triple Negative Breast Cancer Patients. 2022 , 11, 75-88	
477	Proteomic and metabolomic profiling combined with studies reveal the antiproliferative mechanism of silver nanoparticles in MDA-MB-231 breast carcinoma cells.. 2022 ,	0
476	CD81 partners with CD44 in promoting exosome biogenesis, tumor cluster formation, and lung metastasis in triple negative breast cancer.	
475	Triple-Negative Breast Cancer with Dermatomyositis: A Case Report and Literature Review.. 2022 , 14, 569-576	
474	New insights into the discovery of drugs for triple-negative breast cancer metastasis.. 2022 , 1-12	0
473	Prognostic significance of adipophilin expression in biopsy specimens of patients with triple-negative breast cancer.. 2022 , 23, 127	1

472	Characterization of TR-107, a Novel Chemical Activator of the Human Mitochondrial Protease ClpP.	0
471	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.. 2022 , 14,	3
470	Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency.. 2022 , 10, 845950	0
469	The Role of Extracellular Matrix Proteins in Breast Cancer.. 2022 , 11,	3
468	Stem Cell Marker Aldehyde Dehydrogenase 1A1 Expression in Triple-negative Breast Carcinoma. 2022 , 10, 287-294	
467	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFB/p65 signaling in triple negative breast cancer.. 2022 , 8, 20	0
466	Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer.. 2022 , 14,	1
465	Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer.. 2022 , 7, 64	1
464	TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers.. 2022 , 41, 32-38	
463	Tumor Dormancy: Biologic and Therapeutic Implications.. 2022 , 13, 8-19	2
462	The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer.. 2022 , 10, 784179	
461	Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors.. 2022 , 12, 4696	0
460	Plant Extract Induces Apoptosis P53 and Signal Transducer and Activator of Transcription 3 Signaling Pathways in Triple-Negative Breast Cancer Cells.. 2022 , 9, 871667	0
459	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.. 2022 , 6, e2000368	1
458	Diagnostic utility of PELP1 and GATA3 in primary and metastatic triple negative breast cancer. 2022 ,	
457	Ribociclib-Loaded Ethylcellulose-Based Nanosponges: Formulation, Physicochemical Characterization, and Cytotoxic Potential against Breast Cancer. 2022 , 2022, 1-11	0
456	A risk model of 10 aging-related genes for predicting survival and immune response in triple-negative breast cancer.. 2022 ,	
455	Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.. 2022 ,	

- 454 ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.. **2022**, 0
- 453 Circular RNA dehydrolidichyl diphosphate synthase facilitated triple-negative breast cancer progression via miR-362-3p/DDX5 axis.. **2022**, 0
- 452 Advanced glycation end products correlate with breast cancer metastasis by activating RAGE/TLR4 signaling.. **2022**, 10, 0
- 451 Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.. **2022**, 0
- 450 Research Progress on Gene Editing Based on Nano-Drug Delivery Vectors for Tumor Therapy.. **2022**, 10, 873369 1
- 449 Clinicopathological Factors Affecting Breast Cancer Survival in Jamaican Women: A Retrospective Review.. **2022**, 1 0
- 448 In Vitro Anti-cancer Effect of Crataegus oxyacantha Berry Extract on Hormone Receptor Positive and Triple Negative Breast Cancers via Regulation of Canonical Wnt Signaling Pathway.. **2022**, 1 0
- 447 THE STABILIZATAION OF C-MYC BY THE NOVEL CELL CYCLE REGULATOR, SPY1, DECREASES EFFICACY OF BREAST CANCER TREATMENTS. 0
- 446 PARP1, BRCA1 and androgen receptor expression in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. **2022**, 0
- 445 The clinical and prognostic significance of CMTM6/PD-L1 in oncology.. **2022**, 1 0
- 444 Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.. **2022**, 6, e2100280 0
- 443 Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.. **2022**, 116739 1
- 442 Metabolic Intervention Nanoparticles for triple-negative Breast Cancer Therapy Via Overcoming FSP1-mediated Ferroptosis Resistance.. **2022**, e2102799 2
- 441 NSMCE2, a Novel Super-Enhancer Regulated Gene, is Linked to Poor Prognosis and Therapy Resistance in Breast Cancer. 2
- 440 Nanoprodrug ratiometrically integrating autophagy inhibitor and genotoxic agent for treatment of triple-negative breast cancer.. **2022**, 283, 121458 2
- 439 Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer.. **2022**, 14, 0
- 438 Exosomal-microRNA transcriptome profiling of Parental and CSC-like MDA-MB-231 cells in response to cisplatin treatment.. **2022**, 233, 153854 1
- 437 Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.. **2022**, 63, 77-84 0

436	Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer.. 2022 , 28, 17-31	1
435	Molecular Mechanisms of Biologically Active Compounds from Propolis in Breast Cancer: State of the Art and Future Directions. 1-38	
434	Lymph Node Ratio as a Good Prognostic Factor for Patients with Pathologic N3a Breast Cancer with 10 or More Metastatic Axillary Lymph Nodes. 2021 , 9, 56-64	0
433	Advances in Analyzing the Breast Cancer Lipidome and Its Relevance to Disease Progression and Treatment.. 2021 , 26, 399	0
432	Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer.. 2021 , 12, 799428	2
431	Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.. 2021 , 12, 770663	0
430	A uracil auxotroph <i>Toxoplasma gondii</i> exerting immunomodulation to inhibit breast cancer growth and metastasis.. 2021 , 14, 601	0
429	Synergistic strategy with hyperthermia therapy based immunotherapy and engineered exosomesâposomes targeted chemotherapy prevents tumor recurrence and metastasis in advanced breast cancer.	0
428	Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.. 2021 , 14,	0
427	EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis.. 2022 , 30, 157-164	0
426	Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study. <i>Clinical Cancer Research</i> , 2021 ,	12.9 1
425	Palbosiklibâ Triple Negatif Meme Kanseri Hâre Hatlarâ (MDA-MB-231 ve MDA-MB-468) âzerine Sitotoksik Etkisi. 806-814	
424	Adjuvant Versus Neoadjuvant Systemic Therapy. 2022 , 151-167	
423	The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States.. 2021 , 39, 943	0
422	Design and synthesis of chromone-nitrogen mustard derivatives and evaluation of anti-breast cancer activity.. 2022 , 37, 431-444	1
421	Passerini chemistries for synthesis of polymer pro-drug and polymersome drug delivery nanoparticles.. 2022 ,	2
420	Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern.. 2022 , 12, 830124	0
419	A neutrophil-mediated carrier regulates tumor stemness by inhibiting autophagy to prevent postoperative triple-negative breast cancer recurrence and metastasis.. 2022 ,	0

- 418 The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis.. **2022**, 1 0
- 417 A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time.. **2022**, 12, 6352
- 416 LINC01605 promotes aerobic glycolysis through LDHA in triple-negative breast cancer.. **2022**, 0
- 415 CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer.. **2022**, 13, 862125 0
- 414 Inhibition of endoplasmic reticulum stress alleviates triple-negative breast cancer cell viability, migration, and invasion by Syntenin/SOX4/Wnt/ β -catenin pathway via regulation of heat shock protein A4.. **2022**, 13, 10564-10577 2
- 413 Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation.. **2022**, 58, 3
- 412 Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer.. **2022**, 23, 3
- 411 Data_Sheet_1.PDF. **2018**,
- 410 table_1.docx. **2018**,
- 409 data_sheet_1.PDF. **2018**,
- 408 Data_Sheet_1.PDF. **2020**,
- 407 Image_1.TIF. **2019**,
- 406 Image_2.TIF. **2019**,
- 405 Image_3.TIF. **2019**,
- 404 Image_4.TIF. **2019**,
- 403 Image_1.TIF. **2020**,
- 402 Table_1.DOCX. **2020**,
- 401 Image_1.TIF. **2019**,

400 Image_2.TIF. **2019**,

399 Data_Sheet_1.pdf. **2019**,

398 Data_Sheet_1.docx. **2019**,

397 Data_Sheet_1.docx. **2018**,

396 Data_Sheet_1.docx. **2020**,

395 Image_1.TIF. **2020**,

394 Image_2.JPEG. **2020**,

393 Image_1.jpg. **2020**,

392 Image_2.jpg. **2020**,

391 Image_3.tif. **2020**,

390 Image_4.jpg. **2020**,

389 Image_5.jpg. **2020**,

388 Table_1.DOCX. **2020**,

387 Table_2.DOCX. **2020**,

386 Table_3.DOCX. **2020**,

385 Table_4.DOCX. **2020**,

384 Table_5.DOCX. **2020**,

383 Table_6.DOCX. **2020**,

382 DataSheet_1.zip. **2020**,

381 DataSheet_2.pdf. **2020**,

380 Data_Sheet_1.pdf. **2019**,

379 Image_1.TIFF. **2019**,

378 Table_1.DOCX. **2019**,

377 Table_2.DOCX. **2019**,

376 Table_3.DOCX. **2019**,

375 Table_4.DOCX. **2019**,

374 Table_5.DOCX. **2019**,

373 Table_6.DOCX. **2019**,

372 Table_1.DOCX. **2018**,

371 Table_2.DOCX. **2018**,

370 Data_Sheet_1.pdf. **2019**,

369 Image_1.pdf. **2019**,

368 miR-1290 modulates the radioresistance of triple-negative breast cancer by targeting NLRP3-mediated pyroptosis.. **2022**, 1

1

367 Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC.. **2022**,

0

366 Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.. **2022**, 20, 136

1

365 CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1.. **2022**, 41, 149

2

364	Association of machine learning ultrasound radiomics and disease outcome in triple negative breast cancer.. 2022 , 12, 152-164		
363	MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of .. 2022 , 14, 2021-2036		
362	Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing. 25,		
361	Triple-negative breast cancer - an aggressive subtype of breast cancer. 2022 , 1-28		
360	Conventional adjuvant chemotherapy in combination with surgery, radiotherapy, and other specific targets. 2022 , 95-120		4
359	An Update on the Effect of Natural Products on Oncogenic Transcription Factors in Triple Negative Breast Cancer. 2022 , 1-26		
358	Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). 2022 , 15, 542		0
357	Outcomes of Immediate Breast Reconstruction in Triple Negative Breast Cancer: A Propensity Score-Matched Analysis. 2022 ,		
356	Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer.. 2022 , 11,		0
355	Kinesin family member 23, regulated by FOXM1, promotes triple negative breast cancer progression via activating Wnt/βcatenin pathway.. 2022 , 41, 168		1
354	Intelligent Biomimetic Nanoplatfrom for Systemic Treatment of Metastatic Triple-Negative Breast Cancer Enhanced EGFR-Targeted Therapy and Immunotherapy.. 2022 ,		1
353	Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer.. 2022 , 23, 197		0
352	A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.. 2022 ,		1
351	Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer.. 2022 ,		
350	Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin(IV) Prodrugs for Safer Synergistic Chemotherapy.. 2022 ,		0
349	Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.. 2022 ,		
348	Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	1
347	Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy.. 2022 , 17, 55		4

- 346 PD-L1 expression in Congolese women with triplenegative breast cancer. **2022**, 13, 61-63
- 345 Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies. **2022**, ○
- 344 Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer. **2022**, 87-112
- 343 Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies. 1 ○
- 342 Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer: a comprehensive update.. **2022**, ○
- 341 Ginsenoside CK induces apoptosis in triple-negative breast cancer cells by targeting glutamine metabolism. **2022**, 115101 ○
- 340 Heme Oxygenase Modulation Drives Ferroptosis in TNBC Cells. **2022**, 23, 5709 2
- 339 Wnt Signaling in the Breast: From Development to Disease. **2022**, 10, 1
- 338 Learning from Small Medical Data - Robust Semi-Supervised Cancer Prognosis Classifier with Bayesian Variational Autoencoder.
- 337 Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. **2022**, 1-13 ○
- 336 High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival. 12,
- 335 EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. **2022**, 23, 6122 ○
- 334 Breast Cancer With Relevance for Heavy Metals, Mycotoxines, and Pesticides. **2022**, 357-397
- 333 Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices. **2022**, 10,
- 332 SCAMP3 Regulates EGFR and Promotes Proliferation and Migration of Triple-Negative Breast Cancer Cells through the Modulation of AKT, ERK, and STAT3 Signaling Pathways. **2022**, 14, 2807 1
- 331 Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. **2022**, 16, 117955492210998 2
- 330 Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. **2022**, 4, ○
- 329 Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).

328	Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.	
327	Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer. 2022 , 22,	2
326	Breast Cancer Genomics: Primary and Most Common Metastases. 2022 , 14, 3046	
325	Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness. 2022 , 22,	0
324	Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer. 13,	1
323	Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals. 2022 ,	0
322	Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. 2022 , 23, 6806	2
321	A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm. 12,	2
320	Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer. 2022 , 17, e0270528	0
319	Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism. 2022 , 14, 2896	0
318	Racemic Norlignans as Diastereoisomers from Ferula sinkiangensis Resins with Antitumor and Wound-Healing Promotion Activities. 2022 , 27, 3907	1
317	Comparative analysis of transient receptor potential channel 5 opposite strand-induced gene expression patterns and protein-protein interactions in triple-negative breast cancer. 2022 , 24,	
316	Breast cancer cells mediate endothelial cell activation, promoting von Willebrand Factor release, tumour adhesion and transendothelial migration.	4
315	Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment. 2022 , 20,	0
314	Clinical Outcomes of Hypofractionated Whole Breast Irradiation in Early-Stage, Biologically High-Risk Breast Cancer. 2022 ,	
313	Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells. 2022 ,	
312	VEGF Overexpression Significantly Increases Nanoparticle-Mediated siRNA Delivery and Target-Gene Downregulation. 2022 , 14, 1260	0
311	An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. 2022 , 7, 100502	1

- 310 Three-dimensional hydrophobic platforms for in vitro tumoroid culture. **2022**, 110, 317-322
- 309 Treatment-Related Adverse Events of PD-1 or PD-L1 Inhibitors for Triple Negative Breast Cancer Patients: A Systematic Review and Meta-Analysis.
- 308 Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. **2022**, 26, 513-535 1
- 307 *Origanum syriacum* L. Attenuates the Malignant Phenotype of MDA-MB231 Breast Cancer Cells. 12, 1
- 306 Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
- 305 Enrichment of breast cancer stem cells following cytotoxic chemotherapy is mediated by hypoxia-inducible factors. 1
- 304 Rewiring of the Endocrine Network in Triple-Negative Breast Cancer. 12, 0
- 303 Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics. 0
- 302 Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance. 12, 0
- 301 Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism. **2022**, 10,
- 300 Using deep learning for triple-negative breast cancer classification in DCE-MRI. **2022**,
- 299 Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. 1-20 0
- 298 In vitro radiosensitization of breast cancer with hypoxia-activated prodrugs. 1
- 297 In Vivo Evaluation of (â)Zampanolide Demonstrates Potent and Persistent Antitumor Efficacy When Targeted to the Tumor Site. **2022**, 27, 4244
- 296 Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. **2022**, 1
- 295 Anti-breast cancer sinomenine derivatives via mechanisms of apoptosis induction and metastasis reduction. **2022**, 37, 1870-1883 0
- 294 The landscape of systemic therapy for early stage triple negative breast cancer. 1
- 293 Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer. **2022**, 29, 4748-4767 1

292	Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature.	
291	A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. 2022 , 13,	1
290	Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. 2022 , 8,	0
289	Circulating proteins as predictive and prognostic biomarkers in breast cancer. 2022 , 19,	6
288	Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. 2022 ,	1
287	Fucoxanthinol Promotes Apoptosis in MCF-7 and MDA-MB-231 Cells by Attenuating LamininsâIntegrins Axis. 2022 , 2, 145-163	
286	CostâEffectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.	0
285	The BR2 peptide associated with 2-aminoethyl dihydrogen phosphate is a formulation with antiproliferative potential for a triple-negative breast cancer model. 2022 , 153, 113398	
284	Body mass index increases the recurrence risk of breast cancer: a doseâResponse meta-analysis from 21 prospective cohort studies. 2022 , 210, 26-33	
283	Association of Pathway Mutations With Survival in Taiwanese Breast Cancers. 12,	1
282	Irradiated Triple-Negative Breast Cancer Co-Culture Produces a Less Oncogenic Extracellular Matrix. 2022 , 23, 8265	0
281	Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition. 2022 , 12, 23644-23660	2
280	Strategies for targeting CIB1, a challenging drug target. 2022 , 28,	
279	The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.	
278	The cross-talk of autophagy and apoptosis in breast carcinoma: implications for novel therapies?. 2022 , 479, 1581-1608	2
277	Dietary Polyphenols and its Molecular Mechanism in the Management of Breast Cancer. 2022 , 196-218	
276	Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything. 2022 , 14, 3729	1
275	Identification of the pyroptosis-related prognostic gene signature and characterization of tumor microenvironment infiltration in triple-negative breast cancer. 13,	0

- 274 Imaging Features of Breast Cancer Subtypes on Mammography and Ultrasonography: an Analysis of 479 Patients.
- 273 Clinical studies of Atezolizumab contributing to FDA approvals. 8, 390-395
- 272 Panitumumab-DOTA-111In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitnerium Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer.
- 271 Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. **2022**, 23, 8844 1
- 270 Evaluation of the results of neoadjuvant treatment in patients with HER2 positive breast cancer subtype. **2022**, 103, 587-591
- 269 HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells. 0
- 268 LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells. **2022**, 10, 2003
- 267 Triple negative breast cancer and reconstruction: Predictors of recurrence, complications, and mortality. **2022**, 41, 343-350
- 266 Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway. 12, 0
- 265 Triple negative breast cancer: approved treatment options and their mechanisms of action. 1
- 264 Interleukin-3-Receptor- β in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target. **2022**, 14, 3918 0
- 263 Proteogenomic markers of chemotherapy resistance and response in triple negative breast cancer. 2
- 262 Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression. 0
- 261 p53 missense mutation is associated with immune cell PD-L1 expression in triple-negative breast cancer. 1-28
- 260 Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study. 0
- 259 Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis.
- 258 Triple negative breast cancer: Pitfalls and progress. **2022**, 8, 8
- 257 Prognostic factors for cancer-specific survival in 220 patients with breast cancer: A single center experience.

- 256 Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures. **2022**, 119, 0
- 255 Varying outcomes of triple-negative breast cancer in different age groups - prognostic value of clinical features and proliferation.
- 254 Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. 9, 2
- 253 Albumin-Coated Framework Nucleic Acids as Bionic Delivery System for Triple-Negative Breast Cancer Therapy. 1
- 252 Targeted Regulation and Cellular Imaging of Tumor-Associated Macrophages in Triple-Negative Breast Cancer: From New Mechanistic Insights to Candidate Translational Applications.
- 251 High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer.
- 250 CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer. 13, 3
- 249 Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. 12, 3
- 248 Synthesis, In Vitro and in Cell Study of a New Spirooxindoles-Based N-Alkylated Maleimides Targeting HER2/3 Signaling Pathway. 1-25
- 247 Diagnostic and Prognostic Nomograms for Lung Metastasis in Triple-Negative Breast Cancer. **2022**, 2022, 1-12
- 246 The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer.
- 245 A comprehensive review on novel delivery approaches for exemestane. **2022**, 75, 103655
- 244 Dual function miR-205 is positively associated with ER and negatively with five-year survival in breast cancer patients. **2022**, 238, 154080 0
- 243 Racial Disparity in Quadruple Negative Breast Cancer: Aggressive Biology and Potential Therapeutic Targeting and Prevention. **2022**, 14, 4484 0
- 242 Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study. **2022**, 238, 154137 1
- 241 Advancement of cell-penetrating peptides in combating triple-negative breast cancer. **2022**, 27, 103353 0
- 240 Targeting triple-negative breast cancers using nanomedicine. **2022**, 199-255 0
- 239 Can HER2-Low Tumor Be Considered as a Biologically Distinct Subtype with HER2-Zero Tumor in Triple-Negative Breast Cancer: Comparison Clinical Characteristics, Gene Mutation Spectrums, Gene Expression Levels, and Prognosis. 0

238	pH-Responsive, two-in-one doxorubicin and Bcl-2 siRNA-loaded micelleplexes for triple-negative breast cancer therapy.	0
237	Comparison of 7th and 8th American Joint Committee on Cancer Tumor-Node-Metastasis staging in infiltrating ductal carcinoma of the breast: A retrospective study. 2022 , 0	0
236	Topical systems for the controlled release of antineoplastic Drugs: Oxidized Alginate-Gelatin Hydrogel/Unilamellar vesicles. 2023 , 629, 1066-1080	1
235	Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: A meta-analysis. 2022 , 101, e29887	0
234	High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes. 2022 , 8,	1
233	Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments.	0
232	Chromatin Variants Reveal the Genetic Determinants of Oncogenesis in Breast Cancer. 2022 , 12, a041322	0
231	Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy. 28,	0
230	Long term risk of distant metastasis in women with non-metastatic breast cancer and survival after metastasis detection: a population-based linked health records study.	0
229	Mitochondrial Protein Cox7b Is a Metabolic Sensor Driving Brain-Specific Metastasis of Human Breast Cancer Cells. 2022 , 14, 4371	1
228	Can EGFR be a therapeutic target in breast cancer?. 2022 , 1877, 188789	1
227	PHENOTYPIC CHARACTERISTICS OF ANDROGEN RECEPTOR-POSITIVE CANCER IN THE TRIPLE-NEGATIVE BREAST CANCER GROUP. 2022 , 49-60	0
226	Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis.	0
225	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. 2022 , 41,	4
224	BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making. 2022 , 14, 4571	0
223	Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes. 2022 , 14, 4286	0
222	Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness. 2022 , 14, 4280	4
221	Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. 2022 , 8,	0

220	Enhancement of the In Vitro Antitumor Effects of Berberine Chloride When Encapsulated within Small Extracellular Vesicles. 2022 , 14, 1913	0
219	Calcification, Posterior Acoustic, and Blood Flow: Ultrasonic Characteristics of Triple-Negative Breast Cancer. 2022 , 2022, 1-9	0
218	Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. 2022 , 22,	1
217	Assessment of the relationships between Ki67 expression and neoadjuvant treatment response and prognosis in breast cancer using two types of response evaluation systems.	0
216	Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. 12,	0
215	Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer. 2022 , 22,	0
214	Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer. 2022 , 29, 6847-6863	1
213	Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation. 13,	0
212	MYCL promotes the progression of triple-negative breast cancer by activating the JAK/STAT3 pathway. 2022 , 48,	0
211	PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters. 2022 , 11, 5524	1
210	Identification of Six N7-Methylguanosine-Related miRNA Signatures to Predict the Overall Survival and Immune Landscape of Triple-Negative Breast Cancer through In Silico Analysis. 2022 , 2022, 1-16	0
209	Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer. 2022 , 8,	1
208	Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report. 12,	0
207	Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery. 2022 , 14, 4353	0
206	PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer. 2022 , 3, 100741	0
205	A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers. 2022 , 9,	0
204	Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer. 2022 , 17, e0275279	0
203	A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. 2022 , 20,	0

202	Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity. 11,	1
201	Role of epigallocatechin-3-gallate in the regulation of known and novel microRNAs in breast carcinoma cells. 13,	0
200	Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. 2022 , 54, 2581-2597	2
199	Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.	0
198	Breast MRI: Techniques and Indications. 2022 , 165-214	0
197	Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials. 2022 , 13, 14827-14839	0
196	Screening of Key Genes for Triple-Negative Breast Cancer Based on a Differential Co-expression Method. 2022 ,	0
195	CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy. 2022 , 14, 5026	1
194	Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer.	0
193	NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. 2022 , 22,	1
192	Identification and analysis of dysregulated fatty acid metabolism genes in breast cancer subtypes. 2022 , 39,	1
191	Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer. 2022 , 14, 5241	0
190	Role of Cancer Stem-like Cells in the Process of Invasion and Mesenchymal Transformation by a Reconstituted Triple-negative Breast Cancer Cell Population Resistant to p53-induced Apoptosis. 2022 , 55, 169-184	0
189	Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway. 2022 , 39,	1
188	Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile. 2022 , 15, e251656	0
187	A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.	0
186	Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide. 2022 , 23, 11760	2
185	Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. 2022 , 14, 4829	2

184	Subpathway Analysis of Transcriptome Profiles Reveals New Molecular Mechanisms of Acquired Chemotherapy Resistance in Breast Cancer. 2022 , 14, 4878	0
183	Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells. 2022 , 14, 2225	3
182	The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia. 2022 , 14, 2184	0
181	Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists's Perspective. 2022 , 11, 6021	1
180	A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer.	0
179	Mitochondria-Targeted Photosensitizer Based Nanoplatform Loading Glutathione Inhibitor for Enhanced Breast Cancer Photodynamic Therapy. 2022 , 112956	0
178	Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center. 2022 ,	0
177	Effectiveness of hypofractionated and normofractionated radiotherapy in a triple-negative breast cancer model. 12,	0
176	Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancer.	0
175	Varying outcomes of triple-negative breast cancer in different age groups's prognostic value of clinical features and proliferation. 2022 , 196, 471-482	0
174	Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?. 2022 ,	0
173	Design and development of a mitochondrial-targeted photosensitizer for two-photon fluorescence imaging and photodynamic therapy. 2022 ,	0
172	Neighborhood and Racial Influences on Triple Negative Breast Cancer: Evidence from Northeast Ohio.	0
171	MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. 2022 , 13,	2
170	Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.	0
169	Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.	0
168	Andrographolide suppresses the malignancy of triple-negative breast cancer by reducing THOC1-promoted cancer stem cell characteristics. 2022 , 206, 115327	0
167	Mannosylated engineered trichosanthin-legumain protein vaccine hydrogel for breast cancer immunotherapy. 2022 ,	0

- 166 Dietary Diindolylmethane Enhances the Therapeutic Effect of Centchroman in Breast Cancer by Inhibiting Neoangiogenesis. 1-16 1
- 165 Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer. Volume 17, 5209-5227 0
- 164 Androgen receptor function and targeted therapeutics across breast cancer subtypes. **2022**, 24, 2
- 163 Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention. **2022**, 23, 13931 0
- 162 3-Methoxy Carbazole Impedes the Growth of Human Breast Cancer Cells by Suppressing NF- κ B Signaling Pathway. **2022**, 15, 1410 2
- 161 Interactive effects of molecular subtypes with tumor size and extracranial metastatic pattern on risk of brain metastasis in breast cancer patients: A population-based study. 0
- 160 Effect of histone deacetylase 8 gene deletion on breast cancer cellular mechanism in vitro and in vivo study. **2022**, 311, 121156 0
- 159 Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation. 0
- 158 Enzymatic Digestion of Cell-surface Heparan Sulfate Alters the Radiation Response in Triple-negative Breast Cancer Cells. **2022**, 0
- 157 In the literature: November 2022. **2022**, 7, 100643 0
- 156 Ceramide Synthase 6 Mediates Triple-Negative Breast Cancer Response to Chemotherapy Through RhoA- and EGFR-Mediated Signaling Pathways. 25, 0
- 155 Prognosis and risk factors of advanced breast cancer. **2022**, 0
- 154 Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer. **2023**, 187, 106628 0
- 153 Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer. **2023**, 241, 108331 0
- 152 The role of MEOX1 in non-neoplastic and neoplastic diseases. **2023**, 158, 114068 0
- 151 Benzophenone-3 exposure alters composition of tumor infiltrating immune cells and increases lung seeding of 4T1 breast cancer cells. **2023**, 7, 100080 0
- 150 Triple-Negative/Basal-Like Breast Carcinomas. **2022**, 445-462 0
- 149 Development of anti-membrane type 1-matrix metalloproteinase nanobodies as immunoPET probes for triple negative breast cancer imaging. 9, 0

- 148 Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation. 12, 0
- 147 SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration. 0
- 146 Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer. **2022**, 44, 5848-5865 0
- 145 EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. **2022**, 13, 1
- 144 Estimating the incidence of breast cancer recurrence using administrative data. 0
- 143 Serum LPTM4B as a Potential Diagnostic and Prognostic Biomarker for Breast Cancer. **2022**, 2022, 1-9 0
- 142 High-Throughput Cellular Heterogeneity Analysis in Cell Migration at the Single-Cell Level. 2206754 1
- 141 ICAM1-Targeting Theranostic Nanoparticles for Magnetic Resonance Imaging and Therapy of Triple-Negative Breast Cancer. Volume 17, 5605-5619 0
- 140 Is it possible to identify subpopulations of triple negative breast cancer?. **2022**, 13, 352-360 0
- 139 Geometric tumor embolic budding characterizes inflammatory breast cancer. 1
- 138 Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research 1-20 0
- 137 Markers of local kidney cancer recurrence: A surgeon's mistake or a pattern? Review. 039156032211409 0
- 136 Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer. 13, 0
- 135 Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. **2022**, 16, 1
- 134 Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer. 12, 0
- 133 Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer. **2022**, 12, 0
- 132 Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: a monocentric, retrospective comparison. **2022**, 2
- 131 Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer. 9, 0

130	Application of engineered extracellular vesicles to overcome drug resistance in cancer. 12,	0
129	Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy. 12,	0
128	Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of UrokinaseâHuman Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.	0
127	Negatif Meme Kanseri Hastalarda Lokal Rekrens Ve Hastaların Sakalna Etki Eden Faktrler: Tek Merkez Deneyimi.	0
126	DANCR Induces Cisplatin Resistance of Triple-Negative Breast Cancer by KLF5/p27 Signaling. 2022,	0
125	Associations between quantitative measures of TDLU involution and breast tumor molecular subtypes among breast cancer cases in the Black Womenâ Health Study: a caseâbase analysis. 2022, 24,	0
124	Mebendazole Increases Anticancer Activity of Radiotherapy in Radiotherapy-Resistant Triple-Negative Breast Cancer Cells by Enhancing Natural Killer Cell-Mediated Cytotoxicity. 2022, 23, 15493	0
123	Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes. 12,	0
122	Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.	0
121	Evaluating Fate of Emerging Resistance Hitting the Brakes on Conventional Treatment Approach. 2023, 99-122	0
120	Understanding the phytoestrogen genistein actions on breast cancer: Insights on estrogen receptor equivalence, pleiotropic essence and emerging paradigms in bioavailability modulation. 2023, 23,	0
119	Novel Implications of Prognostic Markers to Monitor the Disease: An Overview. 2023, 182-197	0
118	Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. 2023,	0
117	Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review. 2023, 11, 146	1
116	Breast cancer heterogeneity and its implication in personalized precision therapy. 2023, 12,	0
115	Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice. 2023, 11, 2	1
114	Triple negative breast cancer.	0
113	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. 2023, 15, 321	2

112	Prognosis according to the timing of recurrence in breast cancer. 2023 , 104, 1	○
111	Prognosis prediction and risk factors for triple-negative breast cancer patients with brain metastasis: A population-based study.	○
110	Learning from small medical data—Robust semi-supervised cancer prognosis classifier with Bayesian variational autoencoder. 2023 , 3,	○
109	Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts.	○
108	Molecular Sub-Typing and Exploration of Key Signalling Pathways Involved in Complicating the Disease. 2023 , 47-72	○
107	Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. 2023 ,	○
106	Analysis of Changes in the Expression of Selected Genes from the ABC Family in Patients with Triple-Negative Breast Cancer. 2023 , 24, 1257	○
105	AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells. 26,	○
104	Theranostics for Triple-Negative Breast Cancer. 2023 , 13, 272	1
103	Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC. 13,	○
102	Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins. Volume 15, 11-24	○
101	Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment. 2023 , 15, 227	○
100	Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.	○
99	Arachidin-1, a Prenylated Stilbenoid from Peanut, Enhances the Anticancer Effects of Paclitaxel in Triple-Negative Breast Cancer Cells. 2023 , 15, 399	○
98	Kaiso Protein Expression Correlates with Overall Survival in TNBC Patients. 2023 , 12, 370	○
97	Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future. 2023 , 73-98	○
96	SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer. 12,	○
95	EGF-conjugated bio-safe luteolin gold nanoparticles induce cellular toxicity and cell death mediated by site-specific rapid uptake in human triple negative breast cancer cells. 2023 , 80, 104148	○

- 94 Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review. **2023**, 114, 102511 ○
- 93 HMGA1 Regulates the Expression of Replication-Dependent Histone Genes and Cell-Cycle in Breast Cancer Cells. **2023**, 24, 594 ○
- 92 Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. 1
- 91 Combination of Small Extracellular Vesicle-Derived Annexin A2 Protein and mRNA as a Potential Predictive Biomarker for Chemotherapy Responsiveness in Aggressive Triple-Negative Breast Cancer. **2023**, 15, 212 ○
- 90 The Role of Glucocorticoids in Breast Cancer Therapy. **2023**, 30, 298-314 ○
- 89 A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. **2022**, 8, ○
- 88 Oncologic Safety of Nipple-Sparing Mastectomy for Breast Cancer in BRCA Gene Mutation Carriers: Outcomes at 70 Months Median Follow-Up. ○
- 87 Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy. ○
- 86 Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers. **2023**, 22, 153303382211459 ○
- 85 Sialyl LewisX/A and Cytokeratin Crosstalk in Triple Negative Breast Cancer. **2023**, 15, 731 ○
- 84 Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis. **2023**, 13, 372 ○
- 83 MiR-526b targets lncRNA SLC16A1-AS1 to suppress cell proliferation in triple-negative breast cancer. ○
- 82 Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses. **2023**, 15, 445 ○
- 81 Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. **2023**, 15, 175883592211461 ○
- 80 Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. **2023**, 13, ○
- 79 Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy. **2023**, 13, 190 ○
- 78 MiR-651-3p/CAV1/EGFR axis Modulates Progression and Vasculogenic Mimicry in Triple-negative Breast Cancer. ○
- 77 Experiencia con ixabepilona como tratamiento de primera línea para el cáncer de mama metastásico en América Latina. **2023**, 17, ○

76	Introduction to Breast Cancer. 2023 , 1-22	o
75	<i>>Dictyostelium</i> Differentiation-inducing Factor Derivatives Reduce the Glycosylation of PD-L1 in MDA-MB-231 Human Breast Cancer Cells. 2023 ,	o
74	Effect of Lantana camara ethanolic leaf extract on survival and migration of MDA-MB-231 triple negative breast cancer cell line.	o
73	PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions. 2023 , 30, 1082-1095	o
72	Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers.	o
71	Spider venom-derived peptide JZTX-14 prevents migration and invasion of breast cancer cells via inhibition of sodium channels. 14,	o
70	Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance.	o
69	Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. 2023 , 25,	o
68	Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy. 2023 , 15, 2194	o
67	Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior. 2023 , 36, 100125	o
66	Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response. 2023 , 158, 106836	o
65	Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER&Medicare study. 2023 , 185, 69-82	o
64	Fluorogenic bisazide cyanine probe as a highly efficient acrolein detection tool for diagnosing triple negative breast cancer. 2023 , 380, 133404	o
63	FD-1050@NPs-cRGD: A novel NIR-II fluorophore for triple-negative breast cancer imaging. 2023 , 82, 129153	o
62	Artificial intelligence-based digital scores of stromal tumour-infiltrating lymphocytes and tumour-associated stroma predict disease-specific survival in triple-negative breast cancer. 2023 , 260, 32-42	o
61	Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. 2023 , 26, 106064	o
60	Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. 2023 , 23, 41-51	o
59	PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials. 2023 , 91, 203-217	1

- 58 Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. **2023**, 24, 2969 ○
- 57 An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors. **2023**, 10, ○
- 56 Rational Drug Design of Targeted and Enzyme-Cleavable Vitamin E Analogs as a Neoadjuvant to Chemotherapy: In Vitro and In Vivo Evaluation on Reduction of the Cardiotoxicity Side Effect of Doxorubicin. **2023**, 6, 372-386 ○
- 55 Metabolomics Profiling Reveals the Role of PEDF in Triple-Negative Breast Cancer Cell MDA-MB-231 under Glycaemic Loading. **2023**, 15, 543 ○
- 54 Coating of chitosan on poly D,L-lactic-co-glycolic acid thymoquinone nanoparticles enhances the anti-tumor activity in triple-negative breast cancer. 11, ○
- 53 A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: Progress in the past 17 years. 10, ○
- 52 Recent progress in gold and silver nanoparticle mediated drug delivery to breast cancers. **2023**, 291-328 ○
- 51 The Potential of PSMA as a Vascular Target in TNBC. **2023**, 12, 551 ○
- 50 GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers. 13, ○
- 49 Neighborhood and racial influences on triple negative breast cancer: evidence from Northeast Ohio. **2023**, 198, 369-381 ○
- 48 Recent Advances in Optimizing Radiation Therapy Decisions in Early Invasive Breast Cancer. **2023**, 15, 1260 ○
- 47 Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer. 13, ○
- 46 Metabolomics Analysis Reveals Novel Targets of Chemosensitizing Polyphenols and Omega-3 Polyunsaturated Fatty Acids in Triple Negative Breast Cancer Cells. **2023**, 24, 4406 ○
- 45 The expression of Rab5 and its effect on invasion, migration and exosome secretion in triple negative breast cancer. **2023**, 27, 157-165 ○
- 44 Comparison of clinicopathological characteristics, disease free survival and recurrence in triple negative breast cancer(TNBC) with Non-TNBC. **2023**, 20-22 ○
- 43 Shaping of the Clinical Landscape of Immunotherapy by PD-L1 Expression in Breast Cancer. **2023**, 1-20 ○
- 42 Nano-baicalein facilitates chemotherapy in breast cancer by targeting tumor microenvironment. **2023**, 635, 122778 ○
- 41 Enhancement of reactive oxygen species production in triple negative breast cancer cells treated with electric pulses and resveratrol. 42-56 ○

- 40 Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. **2023**, 11, 735
- 39 Functional roles of FAP- β in metabolism, migration and invasion of human cancer cells. 13,
- 38 Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer. **2023**,
- 37 Recent advances of CREKA peptide-based nanoplatfoms in biomedical applications. **2023**, 21,
- 36 Disruption of estrogen receptor beta's DNA binding domain impairs its tumor suppressive effects in triple negative breast cancer. 10,
- 35 Effects and Mechanisms of Action of Preussin, a Marine Fungal Metabolite, against the Triple-Negative Breast Cancer Cell Line, MDA-MB-231, in 2D and 3D Cultures. **2023**, 21, 166
- 34 A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. **2023**, 13,
- 33 Cell type-specific intracellular protein delivery with inactivated botulinum toxin.
- 32 RANK is a poor prognosis marker and a therapeutic target in ER -negative postmenopausal breast cancer. **2023**, 15,
- 31 ACAT1-mediated METTL3 acetylation inhibits cell migration and invasion in triple negative breast cancer. **2023**, 24, 99-107
- 30 Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
- 29 Fluorouracil exacerbates alpha-crystallin B chain-mediated cell migration in triple-negative breast cancer cell lines. **2023**, 13,
- 28 Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study.
- 27 In vivo CRISPR screens identify RhoV as a pro-metastasis factor of triple-negative breast cancer.
- 26 Inhibition of PD-L1 and tumor growth in triple-negative breast cancer using a magnetic nanovector with microRNA34a. **2023**, 14,
- 25 Synthesis of Ester-Linked Ursolic Acid-Based Hybrid Compounds: Potential Antibacterial and Anticancer Agents.
- 24 BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib. 13,
- 23 GE11-antigen-loaded hepatitis B virus core antigen virus-like particles efficiently bind to TNBC tumor. 13,

- 22 Estrogen Receptor β Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer. **2023**, 24, 5867
- 21 Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer. Volume 17, 901-917
- 20 Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.
- 19 Aptamer-Based Strategies to Boost Immunotherapy in TNBC. **2023**, 15, 2010
- 18 Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple-Negative Breast Cancer Treatment.
- 17 Tob negatively regulates NF- κ B activation in breast cancer through its association with the TNF receptor complex..
- 16 Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy. 26,
- 15 Comprehensive analysis of glycolysis mediated pattern clusters and immune infiltration characterization of tumor microenvironment in triple-negative breast cancer. **2023**, 9, e15175
- 14 Aberrant accumulation of NIK promotes tumor growth by dysregulating translation and post-translational modifications in breast cancer. **2023**, 23,
- 13 Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells.
- 12 Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC).
- 11 Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers. **2023**, 14,
- 10 Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer. 1-12
- 9 Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
- 8 Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment.
- 7  **2016**, 73-77
- 6 A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. 13,
- 5 Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.

- 4 Cell-Type-Specific Intracellular Protein Delivery with Inactivated Botulinum Neurotoxin. **2023**, 145, 10220-10226
- 3 Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practice. ○
- 2 Hinokitiol-iron complex is a ferroptosis inducer to inhibit triple-negative breast tumor growth. **2023**, 13, ○
- 1 Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study. 13, ○